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DRUG DELIVERY SYSTEMS 
The method by which a drug is delivered can have a significant effect on its efficacy. 
Some drugs have an optimum concentration range within which maximum therapeutic effect is 
achieved and concentrations above or below this range can be toxic or produce no therapeutic 
benefit at all. On the other hand, the very slow progress in the efficacy of the treatment of severe 
diseases has suggested a growing need for a multidisciplinary approach for the delivery of 
therapeutics to targets in tissues (Bhagwat & Vaidhya, 2013). 
New ideas on controlling the pharmacokinetics, pharmacodynamics, non-specific 
toxicity, immunogenicity, biorecognition and efficacy of drugs, a strategy called drug delivery 
systems (DDS) were generated, which are based on interdisciplinary approaches that combine 
polymer science, pharmaceutics, bioconjugate chemistry, and molecular biology. To minimize 
drug degradation and loss,to increase drug bioavailability and fraction of the drug accumulated in 
the required zone and to prevent harmful side effects various drug delivery and drug targeting 
system are currently under development (Bhagwat & Vaidhya, 2013). 
Various Drug Delivery Systems: 
Carrier based Drug Delivery System: 
-Liposomes 
-Nanoparticles 
-Microspheres 
-Monoclonal antibodies 
-Niosomes 
-Resealed erythrocytes as drug carriers 
Transdermal Drug Delivery Systems: 
-Sonophoresis 
-Osmotic pump 
-Microencapsulation 
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DRUG DELIVERY CARRIERS:  
Colloidal drug carrier systems such as micellar solutions, vesicle and liquid crystal as 
well as nanoparticle dispersions consisting of small particles of 10-400 nm diameter show great 
promise as drug delivery system . The goal of developing these formulations is to obtain systems 
with optimized drug oading and release properties ,low toxicity and long shelf life (Aruna 
Rastogi, n.d.). 
 
Figure 1. Different pharmaceutical carriers 
 
MICELLAR SYSTEMS 
Micelles formed by self-assembly of amphiphilic block copolymers (5-50 nm) in aqueous 
solutions are of great interest in drug delivery applications. The drugs can be physically 
entrapped in the core of block copolymer micelles and transported at concentrations that can 
exceed their intrinsic water-solubility. Moreover the hydrophilic blocks can form hydrogen 
bonds with aqueous surroundings and form a tight shell around the micellar core. As a result the 
contents of the hydrophobic core are effectively protected against hydrolysis and enzymatic 
degradation. In addition the corona may prevent recognition by the reticuloendothelial system 
(RES) and therefore preliminary elimination of the micelles from the bloodstream (Bhagwat & 
Vaidhya, 2013). 
A final attractive feature of amphiphilic block copolymers is that their chemical composition, 
total molecular weight and block length ratios can be easily changed, which allows control of the 
size and morphology of the micelles (Bhagwat & Vaidhya, 2013).   
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POLYMERIC MICELLES 
Copolymers with surfactant characteristics can also be used to formulate micelles. 
Micelles formed from copolymers tend to have a relatively narrow size distribution compared to 
standard surfactant micelles. Generally, they also have a lower critical micelle concentration ( 
CMC ) and are more stable. Due to their low CMCs, polymeric micelles are relatively insensitive 
to dilution, thus preventing their rapid dissociation and enhancing their circulation time 
compared to surfactant micelles. Polymeric micelles are built from copolymers with hydrophobic 
components comprising poly(propylene oxide), poly (D,L-lactic acid), poly(ɛ-caprolactone), 
poly(L-aspartate) and poloxamers. For the hydrophilic component, which forms the outer 
hydrophilic shell of the micelle, PEG is commonly used.The use of PEG as the hydrophilic 
component supports the formation of micelles. The hydrated PEG surface created on the micelles 
enhances their plasma half-life by promoting steric hindrance and blocking enzymes and 
antibodies reaching the drug, thereby offering protection to the drug and blocking interactions 
with the mononuclear phagocytic system (MPS).(As in case of PEO, the highly swollen and 
flexible shell may play a crucial role in diminishing the recognition of RES cells towards the 
polymeric micelles –(55)). As the micelles are sufficiently large (>50 kDa) to avoid renal 
excretion yet small enough (<200 nm) to avoid clearance by the liver and spleen, they are able to 
promote the specific accumulation of the micelles at tumour sites and sites of inflammation due 
to passive targeting (Yvonne Perrie, 2013) 
As for dendrimers, the outer surface of the polymeric micelles can be further 
functionalized with targeting groups ( such as folate, sugar residues or proteins ) to promote their 
application in drug delivery and targeting. The attachment of monoclonal antibodies to reactive 
groups incorporated in the hydrophilic coating of polymeric micelles has also been investigated 
and shown to promote specific interaction of the micelles with antigens corresponding to the 
antibodies. These micelles are often referred to as immunomicelles (Yvonne Perrie, 2013)  
CHEMICAL NATURE (Pavan Kumar Reddy et al., 2015) 
The research work on polymeric micelles has mainly concentrated on copolymers having 
an A-B diblock structure with A, the hydrophilic (shell) and B, the hydrophobic polymers (core) 
respectively. Polymeric micelles formation includes multiblock copolymers such as 
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) (A-B-A) 
which self-organizes to form the micelles. During the micelle formation drugs can be 
incorporated to form drug carrier systems.  
The hydrophobic core which generally consists of a biodegradable polymer such as 
poly(propylene oxide) (PPO), poly(b-benzyl-1-aspartate) (PBLA), poly(di-lactic acid) (PDLLA) 
or poly (e-caprolactone) acts as a reservoir for an hydrophobic drug and protects it from 
contacting with aqueous environment. 
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The core may also be a water soluble polymer (e.g., poly(aspartic acid)) which is 
rendered hydrophobic by the chemical conjugation of a hydrophobic drug or through association 
between two oppositely charged polyions (polyion complex micelles). 
The poly(ethylene oxide) (PEO) or polyethylene glycol (PEG) is the most commonly 
used material to form hydrophilic shell. The shell is responsible for micelle stabilization and 
interactions with cell membranes and plasmatic proteins. The biodistribution of polymeric 
system is usually dictated by nature of these hydrophilic shell. 
BENEFITS OF USING PLURONICS (Poly(ethylene oxide)-poly(propylene oxide) block 
copolymers): (Diego Chiapetta & Alejandro Sosnik, 2007) 
Micelles formed using pluronic copolymers have following advantages. 
 Polymeric micelles are kinetically stable so they dissociate slowly, even at concentrations 
below the CMC, extending circulation times in blood. 
 Micelles with blocks made of poly(ethylene oxide) are sterically stabilized(stealth) and 
undergo less opsinization and uptake by the macrophages of the 
reticuloendothelialsystem (RES), allowing the micelles to circulate longer in blood. 
 Even though PEO-PPO-PEO materials are non-degradable, molecules with a molecular 
weight in the 10-15kDa range are usually filtered by the kidney and cleared in the urine. 
MECHANISM OF MICELLE FORMATION (Pavan Kumar Reddy et al., 2015) 
There are two forces which helps in formation of micelles 
-An attractive force which leads to the association of molecules and 
-A repulsive force which prevents the infinite growth of the micelles to a distinct macroscopic 
phase.  
The process of micellization of amphiphilic copolymers is similar to the process for 
surfactants. At low concentrations the polymers exist as single chains and as the concentration 
increases to its critical value called as the critical micelle concentration (CMC) the polymer 
chains start to associate and form micelles. In this system, when water is used as a solvent, the 
hydrophobic core part of the copolymer avoid contact with aqueous environment while forming 
micellar structure 
BIODISTRIBUTION AND STABILITY OF MICELLE STRUCTURE 
The threshold concentration for assembly of polymeric micelles is critical micellar 
concentration. Polymeric micelles may not necessarily dissociate immediately after extreme 
dilution because they have a remarkably low CMC (10
-6 – 10-7) which is 1000 folds lower than 
that of surfactant micelles (Nobuhiro Nishiyama & Kazunori Kataoka, 2006). Polymeric micelles 
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behave as large particle that evade the renal excretion during delivery to their site of action, 
while they eventually disassemble into small single polymer chains that can be excreted from the 
bloodstream at kidney (Masayuki Yokoyama, 2014). 
 
Figure 2. Polymeric micelles as drug carriers 
The disassembling rate is an important factor for a good balance between the targeting efficiency 
and the low toxicity and it is also important for drug release rate because drugs are expected to 
be released instantaneously upon the disassembly of micelle structures (Masayuki Yokoyama, 
2014). 
PREPARATION OF DRUG LOADED POLYMERIC MICELLES (Pavan Kumar Reddy et 
al., 2015) 
Drug loaded polymeric micelle can be prepared by following approaches  
 Direct dissolution 
 Solvent evaporation or film rehydration method and 
 Dialysis 
 Freeze drying method 
Direct dissolution: The simplest technique for preparing drug loaded polymeric micelles is 
through direct dissolution of amphiphilic copolymer and drug in water. At or above CMC, the 
copolymer and the drug self-associate in water to form drug loaded micelles. But this method is 
usually associated with low drug loading. To enhance drug loading this technique can be 
combined with an increase in temperature or alternatively a thin evaporated film of a drug can be 
prepared before the addition of copolymer 
Solvent evaporation: In this a volatile organic solvent is used to dissolve the copolymer and the 
drug. A thin film of drug and copolymer is obtained after the solvent is removed by evaporation. 
Drug-loaded polymeric micelles are obtained by reconstituting the film with water. 
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Dialysis: This method is used when the two above mentioned techniques are unsuitable as in 
case when the core forming blocks are long and more hydrophobic. Micelles from such 
copolymers have more potential to solubilize large amounts of  hydrophobic drugs. In these 
cases, the dialysis technique can be used to prepare drug loaded micelles. Solutions of the drug 
and the polymer in organic solvent areplaced in the dialysis bag  and the solvent is exchanged 
with water by immersing bag into water thereby inducing micelle assembly. But the dialysis 
method often requires more than 36 hours for efficient loading. 
Freeze drying method: The above mentioned limitations can be overcome by employing a 
simple and cost effective method in which water/tert-butanol mixture is used for dissolving drug 
and  polymer and then the solution is lyophilized. Drug loaded polymeric micelles are then 
obtained by redispersing the lyophilized product in suitable vehicle. This method is called Freeze 
drying method.                    
ADVANTAGES OF POLYMERIC MICELLES (Pavan Kumar Reddy et al., 2015) 
 Very small particle size (10-100nm): This condition is important for selected drug 
administration routes (such as extravasation into solid tumors, or percutaneous lymphatic 
delivery). From a practical point of view, the micelles preparation are easy to handle, 
prepare and sterilize by filtration because of their small size. 
 High structural stability  
 Large amount of drug loading: Polymeric Micelle carrier system incorporates a large 
amount of hydrophobic drugs within the inner core and makes them available at the site 
of interest 
 High water solubility: The combined hydrophilic/hydrophobic structure help improve the 
solubility of poorly water soluble drugs 
 Low toxicity: Polymers used to synthesize PMs are known to be less toxic than low-
molecular-weight surfactants, such as sodium dodecyl sulphate. PMs are considered very 
safe in relation to chronic toxicity, as it possess much larger size than that for critical 
filtration in the kidney, hence it can evade renal filtration. On the other hand, all polymer 
chains can be dissociated (as single polymer chains) from the micelles over a long time 
period. This phenomenon results in the complete excretion of the block copolymers from 
renal route if the polymer chains are designed with a lower molecular weight than the 
critical value for renal filtration. This is a significant advantage for PMs over the 
conventional (nonmicelle forming) and nonbiodegradable polymeric drug carrier 
systems. 
 Incorporation of various diagnostic agents: PMs can also be modified to incorporate 
routinely used diagnostic agents . Most frequently used diagnostic moieties for three 
major imaging modalities chelated radioactive metals such as 
111
In or 
99m
Tc, for 
scintigraphy; chelated paramagnetic metals such as Gd, for magnetic resonance imaging 
(MRI) and organic iodine for X-ray computed tomography (CT). Polymeric micelles 
have been synthesized incorporating all of the above diagnostic agents 
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DISADVANTAGES OF POLYMERIC MICELLES (Pavan Kumar Reddy et al., 2015) 
Though Polymeric micelles have several advantages and are routinely used for drug delivery 
applications, they suffer from a few limitations that warrants improvement in their design and 
development to advance this field further. These limitations are:
 review, 32
 
 Difficult Polymer synthesis 
            The maintenance of stability of the polymeric micelles will occur by the process of 
cross linking via disulphide bridges or radical polymerization etc., but high levels of polymer 
chemistry are needed in the synthesis of PMs and also in the understanding of the cross 
linking process. Thus to facilitate micelle formation and ensure colloidal stability and to 
overcome this limitation the core-forming block needs to be highly hydrophobic while 
corona forming block needs to be highly hydrophilic. 
 Retention of Drugs with in micelles 
            In the case of some PMs, the encapsulated drug molecule is not retained within the 
micelle during circulation. The drug molecules may diffuse from micelles and bind with 
proteins or cells before they reach the target site. 
 Possible chronic liver toxicity due to slow metabolic process 
            This is the common limitation of polymeric carriers 
APPLICATIONS (Pavan Kumar Reddy et al., 2015) 
 PMs as Diagnostic agents: 
            PMs composed of amphiphilic block copolymers represent a promising class of 
diagnostic agents. Diagnostic agents can be covalently linked to the water-soluble part of 
the polymers or incorporated into the water-insoluble core non-covalently. Resulting 
particles can be used as particulate agents for diagnostic imaging using three major 
imaging modalities-scintigraphy, magnetic resonance imaging (MRI) and X-ray 
computed tomography (CT). PMs have been prepared to incorporate 
111
In or 
99m
Tc, Gd 
and organic iodine for usie in scintigraphy, MRI and CT respectively. 
 PMs as Transepithelial Drug Delivery Vehicle: 
          Transepithelial drug delivery can be attained by polymeric micelles because of 
their ability to internalized into cells and/or cross epithelial barriers, thus the drugs can be 
deliveres either systematically or locally following non-parenteral administration. There 
are two possible routes by which intact polymeric micelles pass across epithelial barriers 
(i) transcellular transport via the process of transcytosis and (ii) paracellular transport 
between epithelial cells due to their relatively small size and hydrophilic surface. 
 PMs as protein Drug Delivery Vehicle: 
         Nano-sized protein encapsulated PMs was prepared by self assembling human 
serum albumn (HSA) as a model protein and degradable block copolymer methyl 
poly(ethylene glycol)-poly(b-amino ester) (PEG-PAE) with piperidine and imidazole 
rings. The result shows that the albumin encapsulated PEG-PAE-API1-(3-Aminopropyl) 
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imidazole (API) can be used as a pH-triggered targeting agent and an effective drug 
delivery system in cerebral ischemia models. Owing to its unique ability of simultaneous 
acid-triggered targeting and effective delivery of proteins, this strategy may be utilized in 
the design of general platforms for delivering other proteins in biomedical field 
 PMs in Oncology: 
          The PM size too large for extravasation fron normal vessel walls and renal 
excretion, and too small from extravasation from blood vessels combined with 
pathophysiological characteristics of hypervascularity, solid tumor tissues, secretion of 
vascular permeability factors, incomplete vascular artichitechture and absence of 
effective lymphatic drainage which leads to enhanced permeability and retention (EPR) 
effect of PM in solid tumors. Apart from its solubilization, small particle size, long 
circulation, targeting and easy production properties, PM system can also alter the drug 
internalization route and subcellular localization, lessen the P-glycoprotein efflux effect, 
consequently, exert a different mechanism of action from the entrapped drugs. 
 pH-Sensitive Polymeric Micelles for Cancer Chemotherapy: 
          Conventional chemotherapeutic agents used for cancer therapy suffer from 
multidrug resistance of tumor cells and has poor antitumor efficacy. Development of pH-
sensitive polymeric micellar delivery systems is one effective approach to improve the 
efficacy of cancer chemotherapy because of physiological differences between the tumor 
tissue and normal tissue. The acid-liable bonds between the therapeutic agents or 
copolymers with reversible protonation-deprotonation core units and the micelle-forming 
copolymers can be used to form pH sensitive PMs for extracellular and intracellular drug 
smart release. pH-sensitive polymeric micelles have been emerging as a fascinating class 
of nano drug carriers for programmable drug targeting delivery in the foreseeable future. 
E.g. Poly(ethylene glycol)-cis-aconityl-chitosan-stearic acid polymeric micelles-
Doxorubicin. 
 Biodegradable PMs for Anticancer Drug Delivery: 
          Biodegradable PMs have emerged as one of the most promising platforms for 
targeted and controlled  anti-cancer drug delivery due to their prolonged circulation time, 
excellent biocaompatibiliy, enhanced accumulation in tumor, and in vivo degradability. 
Biodegradable micelles are of particular interests for co-delivery of two or more 
anticancer drugs, which are released either simultaneously or sequentially to achieve 
synergistic treatment effects (combination cancer therapy). In the future, it is anticipated 
that biodegradable delivery system will play an important role in clinical cancer 
treatments. E.g. Block ionomer complexes (BIC) of poly(ethylene oxide)-b-
polymethacylic acid) (PEO-b-PMA) and divalent metal cations (Ca
2+
) were utilized as 
templates. Disulfide bonds were introduced into the ionic cores by using cystamine as a 
biodegradable cross-linker. Here the drug used is doxorubicin.                
Literature review 
 
Department of Pharmaceutics, Madras Medical College Page 9 
 
      REVIEW OF LITERATURE- PLURONIC POLYMERIC MICELLES 
1. Liyan Zhao et al., formulated curcumin loaded mixed micelles to improve the solubility 
and biological activity of curcumin by thin film hydration method using triblock 
copolymer Pluronic P123 and F68. The mixed polymeric micelle composed of P123 and 
F68 with ratio of 2.05:1 exhibited higher entrapment efficiency and drug loading for 
curcumin. The average size of the curcumin loaded mixed micelles was 68.2 nm and 
showed sustained release ; and the in-vitro cytotoxicity assay showed that Cur-PF 
micelles presented higher cytotoxic effect on MCF-7 and MCF-7/ADR. Based on these 
results , it can be concluded that the mixed micelle formulation developed in this study 
may be considered as a promising drug delivery system for curcumin (Liyan Zhao et al., 
2012). 
2. Ivan Pepic et al., formulated Pluronic F127/L121 mixed micelle system to evaluate it in 
terms of stability upon dilution in biologically relevant media and to explore the 
possibility of preparing F127/L121 micelles in a powder form that can be simply 
reconstituted to an initial freshly made mixed micelle formulation. The mixed F127/L121 
micelles were prepared at a relatively high concentration of Pluronics (1%
w
/w for both 
Pluronics) using two different methods (direct dissolution and film rehydration) with an 
external input of energy (ultrasonication). The size of the optimized micelles was 
approximately 75nm with a narrow size distribution and also satisfied the stability criteria 
upon dilution in different biologically relevant media; where it is stable in PBS upon  
100-fold dilution for atleast 10 days and in PBS containing bovin serum albumin upon 10 
and 50-fold dilution for atleast 48 and 12h respectively. The influence of the type and 
amount of cryoprotectant on the prevention of F127/L121 micelles aggregation during 
the freeze-drying and reconstitution processes shows that the use of trehalose (5%
w
/w) 
and sucrose (2.5%
w
/w) with slow and fast freezing process respectively, resulted in a 
reconstituted product with mostly similar dh and PDI values of the fresh micelle 
formulation (Ivan Pepic et al., 2014). 
3. Zhang Wei et al., formulated Paclitaxel (PTX) loaded mixed micelles to increase its 
cytotoxix effect by thin film hydration method using triblock copolymer Pluronic P123 
and F127. The optimized formulation showed a particle size of about 25nm with 
Encapsulation ratio >90% and a sustained release behavior and in addition micelle 
stability studies implied that introduction of Pluronic F127 (33wt%) into the P123 micelle 
system significantly increased the stability of PTX-loaded micelles. The in-vitro 
cytotoxicity assay on A-549 cells (human lung adenocarcinoma cell line) shows that PTX 
loaded micelle has higher cytotoxic effect when compared to Taxol injection and free 
PTX. Therefore it can be concluded that PTX loaded P123/F127 mixed micelles may be 
considered as an effective anticancer drug deliverysystem for cancer chemotherapy 
(Zhang Wei et al.,2009). 
4. Rania Moataz El-Dahmy et al., formulated Vincopetine loaded mixed micelles to 
increase the in-vivo mean residence time after IV injection by thin film hydration 
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technique using triblock copolymer Pluronic L121 and F127. Simple lattice mixture 
design was for the optimization using Design-Expert software. The optimized formula 
containing 68%
w
/w Pluronic L121 and 32%
w
/w Pluronic F127, had the highest 
desirability value (0.621), Entrapmentefficiency, Particle size, Polydispersity index and 
Zeta potential of the optimized formula were 50.74±3.26%, 161.50±7.39nm, 0.21±0.03 
and -22.42±1.72mv respectively and shows in-vitro sustained release. The in-vivo 
investigation in rabbits, the optimized formula showed a significantly higher elimination 
half-life and mean residence time than the market product. The study demonstrated that 
in-vitro and in-vivo sustainment behavior could be considered as a promising nanocarrier 
for the Intravenous delivery of the hydrophobic drug; Vincopectine , having rapid 
elimination rate with low elimination half-life (Rania Moataz El - Dahmy et al., 2014) 
5. Liangcen Chen et al., formulated Docetaxel loaded mixed micelles to serve as a 
potential antitumor drug delivery system in Taxol-resistant non-small cell lung cancer by 
the thin film hydration method using Pluronic P105 and F127 triblock copolymer. A 
central composite design was utilized to optimize the process , helping to improve drug 
solubilization efficiency and micelle stability. The average size of optimized mixed 
micelle was 23nm, with a 92.40% encapsulation ratio, 1.81% drug loading efficiency and 
in-vitro sustained release. The optimal formulation shows high storage stability in 
lyophilized form, with 95.7% of the drug content remaining after 6 months storage at 
4
o
C. For multidrug-resistant A549/Taxol cells, DTX-loaded P105/F127 mixed micelles 
displayed noticeable anti-tumor efficacy higher than in-vitro Taxotere injection. The 
study demonstrated that DTX-loaded P105/F127 mixed micelles could significantly 
increase the blood circulation time of DTX through pharmacokinetic studies where the 
mixed micelle achieved 1.85 fold longer Mean Residence Time (MRT) in circulation and 
a 3.82 fold larger area under the plasma concentration-time curve than Taxotere. 
Therefore, it could be concluded from the results that DTX-loaded P105/F127 mixed 
micelles might serve as a potential drug delivery system to over come multidrug 
resistance in lung cancer (Liangcen Chen et al.,2013). 
6. Diogo Silva Pellosi et al., attempted to develop Pluronic micelles delivering the 
Photodynamic therapy photosensitizers Benzoporphyrin Derivatives (BPD). The BPDA- 
ring (BPDMA), its regioisomer ring-B (BPDMB) and a BPDMA/BPDMB mixture 
(BPD-Mixt) were formulated in Pluronic P123 or F127 as well as P123/F127 mixed 
micelles at two different mass ratios. This nanocarrier system promoted the encapsulation 
of both A- and B-ring BPD derivatives and their mixture as monomers enhancing 
photophysical properties and stability in aqueous solutions even in diluted conditions. 
The in-vitro experiments showed photoactivity of BPD-Mixt similar to that of BPDMA 
which is of utmost interest due to the use of the under explored B-ring derivative. Indeed 
the expensive separation step of regioisomers is avoided and implies in cost reduction. 
Based on these preliminary results BPD-Mixt loaded in binary P123/F127 micelles 
system allies cost reduction and photodynamic efficiency, which stimulates further 
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development on this nanosystem and may be of clinical interest for cancer photodynamic 
therapy (Diogo Silva Pellosi et al., 2016). 
7. Yanzuo Chen et al., formulated methotrexate loaded Pluronic P105/F127 mixed micelle 
to enhance the antitumor activity of methotrexate (MTX) in multidrug resistanc 
modulation by thin film hydration method. The optimized formulation displayed suitable 
particle size (22nm) and distribution, high drug-loading and pH dependent drug release. 
The MTX cellular uptake in A-549 and KBv MDR cells was much higher in the PF-MTX 
group compared to MTX. PF-MTX displayed higher antitumor efficacy than free MTX in 
both MDR cancerous cell lines. The pharmacokinetic studies demonstrated that PF-MTX 
can significantly increase the blood circulation time of MTX. In-vivo real time studies 
also indicated passive accumulation of polymeric micelles in tumor tissues. Furthermore 
PF-MTX exhibited remarkable antitumor activity against KBv MDR tumor xenografts 
and induced less systemic toxicity in comparison with MTX injection. Taken together, 
PF-MTX micelles are a potential drug delivery system for MDR tumor chemotherapy 
(Yanzuo Chen et al., 2013). 
8. S. S. Kulthe et al., developed mixed micelles by varying the ratio of hydrophobic 
Puronic L81 and relatively hydrophilic Pluronic P123 by taking Aceclofenac (Acl) as a 
model hydrophobe  for drug delivery application. The mixed micelles promise a high 
solubilization potential for hydrophobic drugs and developed small sized micelle 
dispersions (~20nm) with fairly high entrapment efficiency, drug loading and low 
polydispersity indices with sustained release profile for Aceclofenac. The TEM 
demonstrated spherical shape of micelles. Stable dispersions were obtained for 
0.1/1.0wt% and 0.5/3.0wt% Pluronic L81/P123. Micelles were also found to be stable in 
bovine serum albumin solution. Presence of salt lowered Acl solubilization in micelles. 
Thermodynamic parameters for Acl solubilization in mixed micelles revealed high 
partition coefficient values and spontaneity of drug solubilization. Thus the developed 
novel mixed micelles hold promise in controlled and targeted drug delivery owing to 
their vey small size, high entrapment efficiency and stability (Kulthe et al., 2011). 
9. Shilpa Praveen Chaudhari et al., investigated the solubilization of poorly water soluble 
drug Lamtrigine in pure and mixed pluronic polymeric micelles. The polymeric micelles 
containing Lamotrigine were prepared by direct dissolution technique using block 
copolymer (Pluronic L81, Pluronic F68) in combination (1:1) ratio and alone by using 
various drug:polymer ratios. Mixed micelles (hydrophilic and hydrophobic) helped to 
overcome the limitations of monosystem of Pluronic L81 and Pluronic F68. Results show 
that the solubilization of Lamotrigine enhances with the rise in concentration of block 
copolymers and temperature, but no significant increase was observed with added salt 
and at a lower pH the drug show highest solubility. In conclusion mixed micelles showed 
fairly high entrapment efficiency, loading capacity and sustained release profile for 
Lamotrigine than that of plain pluronic micelles (Shilpa Praveen Chaudari & Jayashree 
Ramesh Patil, 2014). 
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10. Suk Hyug Kwon et al., formulated genistein loaded pluronic F127 polymeric micelles 
for oral drug delivery application by solid dispersion method. Drug loading amount and 
drug loaded efficiency were 11.81% and 97.41% respectively. The average size was 
27.76nm and in-vitro release was 58% and 82% in pH 1.2 and pH 6.8 respectively at 12 
hours. The bioavailability of genistein-loaded polymeric micelles was better than 
genistein posder. Consequently, Pluronic F127 polymeric micelles are an effective 
delivery system for the oral administration of genistein (Suk Hyung Kwon et al., 2007). 
 
 
REVIEW OF LITERATURE – RALOXIFENE HYDROCHLORIDE 
1. Sebastien Taurin et al., demonstrated the advantages of encapsulating raloxifene into 
SMA and its cytotoxic potency in two Castrate Resistant Prostate Cancer (CRPC) cell 
lines differing in the level of ERα and ERβ expression compared to free drug. The SMA-
Ral micelles had 132 and 140% higher cytotoxicity against PC3 and DU145 prostate cell 
lines respectively. SMA-Ral effectively inhibits cell cycle progression, increases 
apoptosis and alters the integrity of tumor spheroid models. In addition, the micellar 
system induced changes in expression and localization of estrogen receptors, epidermal 
growth factor receptor (EGFR) and downstream effectores associated with cell 
proliferation and survival. Finally, SMA-Ral treatment decreased migration and invasion 
of CRPC cell lines. In conclusion, SMA-Ral micelles can potentially benefit new 
strategies for clinical management of Castrate Resistant Prostate Cancer (Sebastien 
Taurin et al., 2014). 
2. Anand Kumar Kushwaha et al., prepared Raloxifene loaded Solid Lipid Nanoparticles 
(SLN) using Compritol 888 ATO as lipid carrier and Pluronic F68 as surfactant by 
solvent emulsification/evaporation method to improve the oral bioavailability of 
raloxifene (RL). Particle size of all the formulations were in the range of 250 to 1406nm 
and the entrapment efficiency ranges from 55 to 66%. In-vitro drug release studies were 
performed in phosphate buffer of pH 6.8 using dialysis bag diffusion technique FTIR and 
DSC studies indicated no interaction between drug and lipid, and the XRD spectrum 
showed that RL-Hcl is in amorphous form in the formulation. In-vitro release profiles 
were biphasic in nature and followed Higuchi model of release kinetics. 
Pharmacokinetics of  raloxifene loaded SLN after oral administration to wistar rats was 
studied. Bioavailability of RL-Hcl loaded SLN was nearly five time than that of pure RL-
Hcl (Anand Kumar Kushwaha et al., 2013) 
3. Arpita Patel et al., formulated Raloxifene Hydrochloride (RLH) loaded liposomes by 
thin film hydrartion method using 1:1 molar ratio of DSPC : Cholesterol and investigated 
its uterine targeting efficiency after intravaginal administration. Radiolabelling of RLH 
was performed with reduced technetium-99m (
99m
Tc). Binding affinity of 
99m
Tc- labeled 
complexes. Biodistribution study was done in New Zealand white female rabbits by 
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Gamma scintigraphy revealed the preferential uptake of the formulation by uterus when 
administered vaginally. Spherical and discrete lipososmes of size 119nm were seen in 
TEM results.  Liposomes had high Entrapment Efficiency of 90.96% with Drug Loading 
of 27.25%
w
/w compared to plain drug . Liposomes concentrated and retained with in the 
uterus for a longer period of time. In conclusion, uterine targeting of RLH loaded 
liposomes indicates its potential to overcome the limitations of marketed formulation. 
Drug targeting to site of action anticipates dose reduction needed to elicit the therapeutic 
effect (Arpita Patel et al., 2016). 
4. Manal A Elsheikh et al., Formulated Raloxifene loaded self-nanoemulsifying drug 
delivery systems (SNEDDS) to enhance RLX delivery to endocrine target organs. The 
Raloxifene (RLX) was loaded in the dissolved dispersed status in the alkalinized (A-
SNEDDS) and non alkalinized (NA-SNEDDS) systems respectively. In-vitro release was 
assessed using dialysis bag versus dissolution cup methods. NA-SNEDDS were 
developed with suitable globule size (38.49±4.30), ZP (31.70±3.58mv), PDI (0.31±0.02) 
and cloud point (85
o
C). A-SNEDDS exhibited good globule size (35±2.80nm), adequate 
PDI (0.28±0.06) and lower ZP magnitude (-21.20±3.46mv). TEM revealed spherical 
globules and contended data of size analysis. Release studes demonstrated a 
nonsignificant enhancement of RLX release from NA-SNEDDS compared to drug 
suspension with the lowest release shown by A-SNEDDS. In-vivo studies reflected a poor 
in-vitro/in-vivo correlation in solubilized form (A-SNEDDS). In conclusion, NA-
SNEDDS possessed superior in-vitro characteristics to A-SNEDDS , with equal in-vivo 
potential. NA-SNEDDS elaborated in this work could successfully double RLX delivery 
to endocrine target oragans, with promising consequences of lower dose and side effects 
of the drug (Manal A Elsheikh et al., 2012).  
5. Jaya Prakash Shanmugam, Santhiagu Arockiasamy and Jasemine formulated 
raloxifene loaded gellan gum nanoparticles to develop a better system to deliver poorly 
water soluble hydrophobic drugs like raloxifene Hcl (RLX-Hcl)  by emulsion cross 
linking method. The developed nanoparticles showed narrow particle size distribution 
with an average size of 472nm, zeta potential of -40.6mv along with 98±3% entrapment 
efficiency. FTIR studies demonstrated chemical interaction between the polymer and 
drug. In-vitro release studies showed an initial release within 30 min followed by 
continuous release for 24 hours. In-vitro cytotoxicity studies performed with MCF7 cell 
line revealed that the RLX Hcl-gellan gum nanoparticles exhibit higher cytotoxicity 
compared to free RLX Hcl. The result suggest that gellan gum nanoparticle system can 
be a better system to deliver hydrophobic drug like Raloxifene Hydrochloride (Jaya 
Prakash Shanmugam, Santhiagu Arockiasamy and Jasemine et al., 2014). 
6. Tuan Hiep Tran et al., demonstrated the study to improve the physicochemical 
properties and bioavailability of a poorly water-soluble drug, raloxifene by Solid 
Dispersion (SD) nanoparticles using the spray-drying technique. These spray dried SD 
nanoparticles were prepared with raloxifene (RXF), poly vinyl pyrrolidone (PVP) and 
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Tween 20 in water. Reconstitution of optimized RXF-loaded SD nanoparticles in pH 1.2 
medium showed a mean particle size of approximately 180nm.X-ray diffraction and 
differential scanning colorimetry indicated that RXF existed in amorphous form with in 
spray-dried nanoparticles. The optimized formulation showed an enhanced dissolution 
rate of RXF at pH 1.2, 4.0, 6.8 and distilled water as compared to pure RXF powder. The 
improved dissolution of raloxifene from spray-dried SD nanoparticles appeared to be 
well correlated with enhanced oral bioavailability of raloxifene in rats. Furthermore, the 
pharmacokinetic parameters of the spray dried SD nanoparticles showed increased  
AUC0-∞ and Cmax of RXF by approximately 3.3 fold and 2.3 fold respectively. These 
results suggest that the preparation of RXF-SD nanoparticles using the spray drying 
technique without organic solvents might be a promising approach for improving the oral 
bioavailability of RXF (Tuan Hiep Tran et al.,2013). 
7. Ashok Velpula et al., investigated the feasibility of neutral and charged proliposomes for 
the improved oral delivery of RXH. RXH could be loaded into proliposome formulation 
by film deposition method using spray dried mannitol as carrier. The effect of surface 
charge was studied by tailoring of optimized formulation (RXH- PL3) with diacetyl 
phosphate and stearyl amine. The solid state characterization unravels the transformation 
of crystalline state of RXH to amorphous and /or molecular state. The predicted effective 
permeability coefficient and fraction dose absorbed in humans were much higher for 
anionic and cationic charged proliposomes compared to RXH-PL3 and control 
formulation. A two to three fold improvement in the bioavailability of RXH reveals the 
potential of proliposome formulation and the importance of surface charge on the 
preferential uptake across the GI barrier (Ashok Velpula et al., 2013). 
8. Bhama , S., Sambath Kumar, R. S., and Rajagopal Shanmuga Sundaram  
formulated RLX-Hcl loaded proniosomes by slurry method, where different ratios of 
surfactant and cholesterol were used for preparation and evaluating study. The shape of 
prepared RLX-Hcl loaded proniosomes were spherical with an average particle size of 
690nm with a high encapsulation efficiency of 83.64% and in-vitro drug release of 
99.42% were attained after 24 hrs. The vesicles were quite stable at 5
o
C over a period of 
90 days. Hence it may be concluded that proniosome formulation proved as efficient 
carrier for raloxifene oral delivery ( Bhama, Sambath Kumar & Rajagopal Shanmuga 
Sundaram, 2016). 
9. Dimitrios Bikiaris, Vassilios Karavelidis and Evangelus Karavas  formulated 
Raloxifene Hcl nanoparticle using biodegradable polymers. For this purpose a series of 
novel biodegradable poly (ethylene succinate) (PESu) and poly (propylene adipate) 
(PpAd) were used. The prepared polyesters were characterized by intrinsic viscosity 
measurements, end group analysis, enzymatic hydrolysis, Nuclear Magnetic Resonance 
Spectroscopy (
1H
NMR and 
13
C-NMR) and wide angle X-ray Diffractometry (WAD). 
From the characterization of the copolyesters it was found that only P(ESu-co-PAd) 
90/10, 80/20 and 70/30 were in crystalline form, while all the others remained 
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amorphous. The melting point of the P (ESu-co-PAd) 70/30 is lower from the melting 
point of PpAd. These two polymers characterized as thermosensitive polymers and could 
be appropriate for targeting delivery system. The Raloxifene Hcl nanoparticles have been 
prepared by variation of the coprecipitaion method. WAXD showed that Raloxifene Hcl 
is entrapped in crystalline form and possibility in nanocrystalline shapes within the 
nanoparticles. The particle size distribution showed that the nanoparticles are in the range 
of 200-350nm. It was found that the size of the nanoparticles is higher for the polymers 
with higher content in PAd. The drug release rates from the prepared polyesters are very 
low. It seems that these results depend on the drug’s crystallinity within the nanoparticles 
as well as on the melting point of used polyesters. Finally, it was found the nanoparticles 
with higher particle size mentioned higher release rates (Dimitrios Bikiaris, Vassilios 
Karavelidis and Evangelus Karavas, 2009). 
10. Deepa Saini et al., formulated Raloxifene loaded chitosan Nanoparticles for the 
treatment of osteoporosis with enhanced bioavailability by gelation of chitosan 
tripolyphosphate (TPP) and then by ionic cross-linking. Formlation was optimized and 
in-vitro drug release and in-vivo study were performed. The particle size, entrapment 
efficiency and loading efficiency varied from 216.65 to 1890nm, 32.84 to 97.78% and 
23.89 to 62.46% respectively. Release kinetics showed diffusion-controlled and Fickian 
release pattern. In-vivo study indicated higher plasma drug concentration with 
nanoparticles administered intranasally as compared to drug suspension administered 
through oral route (P<0.05). A significant higher drug concentration in plasma was 
achieved in 10min after nasal administration with respect for oral administration. In 
conclusion, the results suggest that RLX-loaded chitosan Nanoparticles have better 
bioavailability and would be a promising approach for intranasal delivery of Raloxifene 
for the treatment of osteoporosis (Deepa Saini et al., 2015). 
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AIM OF THE WORK 
 The aim of the present study is to formulate Raloxifene hydrochloride Polymeric 
Micelle drug delivery system using mixture of triblock copolymers, Pluronic L121 
and F127 by thin film hydration method. 
 
OBJECTIVE 
 To provide an efficient dosage form to improve the therapeutic efficacy  by protection 
of Raloxifene hydrochloride (RXH) from extensive first pass metabolism (Authority 
of the Board of the American Society of Health System, 2011) and thereby improving 
the bioavailability. 
 To overcome its limitation of poor aqueous solubility (Helga Handottir, 2008). 
 
PLAN OF WORK  
 Drug excipients compatibility studies- FT-IR study 
 Determination of λmax of Raloxifene Hydrochloride in Phosphate buffer pH 6.8 
 Calibration curve of the drug in phosphate buffer pH 6.8 
 Formulation of Raloxifene Hydrochloride Pluronic Polymeric Micelles using 
optimized formulation parameters with different concentrations of hydrophilic 
(Pluronic F127) and hydrophobic (Pluronic L121) copolymers   
 Evaluation of Raloxifene Hydrochloride Mixed Pluronic Polymeric Micelles 
 Entrapment Efficiency 
 In-vitro drug release study using  pH 6.8 phosphate buffer containing 
0.5%
v
/v polysorbate 80 by dialysis bag method 
 In-vitro release kinetics 
 Determination of particle size distribution, polydispersity index (PDI) and zeta 
potential analysis using Malvern zeta analyzer 
 Selection of best formulation 
 Concentration of best forulation by lyophilization using cryoprotectant (2.5%w/w 
sucrose) 
 Morphological studies using Confocal Microscopy 
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RATIONALE OF THE STUDY (Ernico M. Messali & Conoscaffa, 2009)
 
           Osteoporosis is a systemic skeletal disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue, with a consequent decrease in bone 
mineral density (BMD) and increase in bone fragility and susceptibility to fracture. 
           The decreased estrogen circulating level during postmenopausal age represents the 
main cause of bone loss and osteoporosis and about 54% of women aged 50 years or 
older will have an osteoporotic fracture during their lifetime. A rapid decrease of bone 
mass is evident in the first 5 to 10 years following the menopause and the annual rate of 
bone loss is at a maximum of about 4% during the former 4 years, then declines to 1%.  
In this period, the physiological bone remodeling is characterized mainly by a relevant 
prevalence of the resorption due to osteoclastic activity. 
          There are several drugs to treat postmenopausal Osteoporosis but adherence to 
osteoporosis medications is relatively poor approximately 20% to 30% of patients taking 
daily or weekly treatments may suspend their treatment within 6 to 12 months of 
initiating therapy. The majority of patients who discontinue therapy appear to do so 
because of drug induced adverse effects and fear of health risks. Asian women showed a 
greater propensity  to remain on raloxifene, compared with bisphosphonates, and the 
women on raloxifene exhibited lower discontinuation rates and higher treatment 
satisfaction, which addressed the more favorable compliance and tolerance with 
raloxifene than with bisphosphonates. Postmenopausal women with osteoporosis, who 
have poor compliance when taking alendronate, can be switched to raloxifene, because 
they can still see benefi ts in BMD and bone turnover with raloxifene after discontinuing 
alendronate therapy. 
  
 RATIONALE FOR SELECTION OF DRUG
 
          Raloxifene hydrochloride is a non-steroidal selective estrogen receptor modulator 
(SERM) which has marketed for use in prevention and treatment of postmenopausal 
osteoporosis. One of the consequences of the Women’s Health Initiative has been 
increased interest in the SERMs, because of the potential to retain most of the beneficial 
effects of estrogen while avoiding some of the adverse effects. Raloxifene binds to 
estrogen-receptors with estrogen agonistic effects in some tissues and estrogen 
antagonistic effects in others. In the last few years, a number of clinical studies have been 
published on the effects of raloxifene on osteoporosis, the risk of invasive breast cancer 
and cardiovascular diseases. There are a number of other SERMs currently under 
investigation but raloxifene is the only SERM currently on the market for osteoporotic 
fractures (Helga Handsdottir, 2008). 
          Raloxifene hydrochloride (RXH) is an orally selective estrogen receptor modulator 
(SERM) with poor bioavailability due to its poor aqueous solubility and extensive first 
pass metabolism where approximately 60% of an oral dose is absorbed , but presystemic 
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glucuronide conjugation is extensive. Absolute bioavailability as unchanged raoxifene is 
2.0% (ASHP, 2011). 
         To overcome these problems and in order to improve the oral bioavailability of 
raloxifene, RXH loaded polymeric micelle have been developed using pluronic L121and 
pluronic F127.  
     
 RATIONALE FOR SELECTION OF POLYMERIC MICELLAR FORMULATION 
 
          The purpose of this research work was to formulate and optimize the Pluronic 
F127/L121 mixed micelle system containing RXH to enhance its solubility and 
therapeutic efficacy by protection from extensive first pass metabolism through reduced 
liver uptake. This can be accomplished by pluronic triblock copolymer whose poly 
(ethylene oxide) block are sterically stabilized (stealth) and undergo less opsonization 
and uptake by the macrophages of the reticuloendothelial system (RES). Another 
advantage of using pluronic is that, even though PEO-PPO-PEO materials  are non 
degradable molecules with a molecular weight in 10-15 KDa range are usually filtered by 
the kidney and cleared in urine (Diego Chiapetta & Alejandro Sosnik, 2007). The 
rationale of using mixture hydrophilic (pluronic F127) and hydrophobic (pluronic L121) 
copolymer is that the hydrophobic pluronic L121 have a relatively high solubilization 
capacity but the micelles formed are large and unstable whereas the hydrophilic pluronic 
F127 form spherical micelles and have a high stability but they have a relatively low 
solubilization capacity. Thus pharmaceutical nanocarriers based on pluronic mixtures 
may overcome the aforementioned deficiencies while improving the solubilization 
capacity and stability of the micelles than that composed of the individual pluronics (Ivan 
Pepic et al., 2014). 
     Pluronic polymeric micelles have been reported to offer the following advantages 
(Diego Chiapetta & Alejandro Sosnik, 2007). 
- Solubilization of water insoluble molecules 
- Protection of unstable agents from chemical degradation and metabolism by 
biological agents 
- Sustained release  
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Osteoporosis is a disease that weakens bones, increasing the risk of sudden and 
unexpected fractures. Literally meaning "porous bone," osteoporosis results in an increased loss 
of bone mass and strength. The disease often progresses without any symptoms or pain. 
Postymenopausal osteoporosis has a direct relationship between the lack of estrogen during 
perimenopause and menopause and the development of osteoporosis. Early menopause (before 
age 40) and any prolonged periods in which hormone levels are low and menstrual periods are 
absent or infrequent can cause loss of bone mass. Estrogen deficiency plays a role in the 
pathogenesis of postmenopausalosteoporosis and of the mechanism of estrogen actionin bone has 
grown considerably. This is mainly a result of the recognition that estrogen regulates bone 
remodeling by modulating the production of cytokines and growth factors from bone marrow 
and bone cells (WebMd L.L.C, n.d.). Postmenopausal osteoporosis should be regarded as the 
product of an inflammatory disease bearing many characteristics of an organ-limited 
autoimmune disorder, triggered by estrogen deficiency, and brought about by chronic mild 
decreases in T cell tolerance (Neale Weitzmann & Roberto Pacifici, 2006).  
PATHOGENESIS AND PATHOPHYSIOLOGY OF POSTMENOPAUSAL 
OSTEOPOROSIS (Nelson Watts et al., 2010) 
Low bone mass and skeletal fragility in adults may be the result of low peak bone mass in 
early adulthood, excessive bone loss in later life, or both. The skeleton is constantly changing 
throughout life. During childhood and adolescence, it changes in size, shape, and constituents by 
a process known as modeling.Change in shape and size is complete with epiphyseal closure at 
the end of puberty, followed by a period of consolidation for 5 to 10 years (depending on the 
skeletal site) until peak adult bone mass is attained, which usually occurs in the late teens or 
early 20s. Approximately 70% to 80% of peak bone mass is genetically determined. Several 
genetic markers have been identified. Many nongenetic factors contribute, including nutrition 
(for example, calcium, phosphate, protein, and vitamin D), load-bearing activity, and hormones 
involved in growth and puberty.  
Once peak adult bone mass has been reached, a process called skeletal remodeling takes 
over, in which old bone is replaced by new bone. Remodeling is governed by the actions of 
osteoclasts that resorb old bone and osteoblasts that produce new bone. Much is known about the 
recruitment and activity of these cells, including the involvement of systemic hormones and local 
cytokines. Recently, the receptor activator of nuclear factor-kb (RANK), its ligand RANKL, and 
a decoy receptor, osteoprotegerin (OPG), have emerged as major local regulators of bone 
remodeling. RANKL, synthesized by osteoblasts and stromal cells and present in the bone 
microenvironment, binds to RANK, expressed in osteoclast progenitor cells in the bone marrow, 
and promotes osteoclastogenesis. OPG is also synthesized by osteoblasts and stromal cells and 
serves as a decoy receptor for RANKL, preventing the binding of RANKL to RANK. Regulation 
of osteoclast activity depends, at least in part, on the balance between RANKL and OPG. The 
relative amount of these 2 molecules is governed, in turn, by systemic hormones (for example, 
estrogen), local factors (such as interleukin-6 and tumor necrosis factor), and perhaps other 
factors as well. The triggering mechanisms that stimulate the cascade of activities that lead to 
remodeling of site-specific quantities of bone are not known. It is well documented, however, 
that this bone remodeling process is in balance (that is, the rate of bone formation equals the rate 
of bone resorption) through at least the fifth decade of life in healthy individuals. 
In women, the hormonal changes that occur throughout perimenopause and the 
immediate postmenopausal years stimulate RANKL production (both directly and indirectly), 
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leading to accelerated bone loss. Most data suggest that the bone turnover rate (and bone loss) 
accelerates 3 to 5 years before the last menstrual period and slows again 3 to 5 years after the last 
menstrual period. With the accelerated bone turnover rate, bone balance is disturbed because 
there is greater net loss than gain in each of the bone remodeling units that are activated. The 
mean rate of bone loss during this period is about 1% per year, or about 10% during the 
menopausal transition. 
 
EFFECTS OF ESTROGEN DEFICIENCY ON BONE TURNOVER AND 
ARCHITECTURE: 
Aging bone is gradually replaced by new tissue through a process called bone remodeling 
or turnover. Bone remodeling occurs through the coordinated action of OBs and OCs. The 
activities of OCs and OBs are combined into defined anatomical spaces called basic multicellular 
units (BMUs). A remodeling cycle begins with the activation of a new BMU on a previously 
inactive surface of bone. This process involves the disappearance of bone-lining cells and their 
replacement by OCs that generate resorption lacunae on the endosteal surface of bone over a 2-
week interval. The resorption phase is then terminated, probably by OC apoptosis, and after a 
brief reversal phase, a team of OBs is recruited that fills in the resorption cavity with new bone. 
The net result is the replacement of a packet of old bone with new bone. At menopause there is a 
transient, accelerated phase of bone loss that is followed by slower, sustained bone loss. 
Although in men there is no abrupt cessation of gonadal function in the sixth decade of life, they 
do experience an age-related decrease in unbound sex steroids resulting from progressive 
increases in circulating sex hormone–binding globulin. In both men and women there is a steady 
decline in unbound (bioavailable) estrogen levels with aging, exacerbated in women at 
menopause by a marked decrease in estrogen levels (Nelson Watts et al., 2010).  
Estrogen deficiency leads to dramatic elevations in the number of BMUs through increased 
activation frequency, which is the number of new remodeling units activated in each unit of time. 
Enhanced activation frequency expands the remodeling space, increases cortical porosity, and 
enlarges the resorption area on trabecular surfaces. This phenomenon is caused primarily by 
increased OC formation, a complex event involving various hematopoietic and immune cells, as 
well as increased OC recruitment to bone surfaces to be remodeled. Estrogen deficiency also 
augments erosion depth by prolonging the resorption phase of the remodeling cycle through 
increased OC lifespan due to reduced apoptosis. The net bone loss caused by the combined 
effects of increased activation frequency and erosion depth is limited in part by a compensatory 
augmentation of bone formation within each remodeling unit. This event is a consequence of 
stimulated osteoblastogenesis fueled by an expansion of the pool of early mesenchymal 
progenitors and by increased commitment of such pluripotent precursors toward the osteoblastic 
lineage. In spite of stimulated osteoblastogenesis, the net increase in bone formation is 
inadequate to compensate for enhanced bone resorption because of an augmentation in OB 
apoptosis, a phenomenon also induced by estrogen deficiency (Nelson Watts et al., 2010). 
An additional event triggered by estrogen withdrawal, which limits the magnitude of the 
compensatory elevation in bone formation, is the increased production of inflammatory 
cytokines such as IL-7 and TNF, which limit the activity of mature OBs. Increased bone 
resorption, trabecular thinning and perforation, and a loss of connection between the remaining 
trabeculae are the dominant features of the initial phase of rapid bone loss that follows the onset 
of estrogen deficiency. This acute phase is followed by a long-lasting period of slower bone loss 
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where the dominant microarchitectural change is trabecular thinning. This phase is due in part to 
impaired osteoblastic activity secondary to increased OB apoptosis (Nelson Watts et al., 2010). 
 
 
Figure 3: Cells and cytokines responsible for physiological OC renewal. OC precursors may 
differentiate from the population of monocytes/macrophages, among which they circulate by 
virtue of their expression of the receptor RANK. When RANKL binds to this receptor in the 
presence of the trophic factor M-CSF, which in turn binds to its receptor, colony-stimulating 
factor receptor 1 (c-Fms), OC precursors differentiate and fuse together to form mature, 
multinucleated bone-resorbing OCs. Under physiological conditions the dominant source of 
RANKL and M-CSF in the bone marrow microenvironment is from the bone-forming cells, the 
OBs, and their SC precursors (Neale Weitzmann & Roberto Pacifici, 2006).
 
 
TREATMENT 
 
 Estrogen Replacement Therapy 
 Selective Estrogen Receptor Modulators 
 Bisphosphonates 
 Calcitonin 
 Parathyroid hormone 
 Other treatment 
 
Estrogen replacement therapy (Neale Weitzmann & Roberto Pacifici, 2006)
 
Initiation of estrogen replacement therapy (ERT) in experimental animals and humans 
decreases erosion depth and OC activation frequency by stimulating apoptosis and blocking 
osteoclastogenesis. Long-term ERT at high doses not only blunts bone resorption but also 
stimulates bone formation, leading to a net anabolic effect. A decrease in OB apoptosis resulting 
from a nongenotropic effect of estrogen is likely a major mechanism driving this effect. 
However, the increase in OB lifespan is offset in part by a repressive effect of estrogen on 
osteoblastogenesis, a phenomenon that explains why the anabolic effect of estrogen is observed 
only at high doses and during long-term treatment 
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Figure 4: Estrogen suppresses T cell TNF production by regulating T cell differentiation and 
activity in the bone marrow, thymus, and peripheral lymphoid organs. In the bone marrow, 
estrogen downregulates the proliferation of hematopoietic stem cells through an IL-7–dependent 
mechanism, resulting in a smaller pool of lymphoid progenitors. T cell precursors leave the bone 
marrow and migrate to the thymus, where T cell differentiation, selection, and expansion take 
place, in large measure under control of IL-7. Following release from the thymus 
(thymic output), these new T cells home to peripheral lymphoid organs, including the bone 
marrow itself. Estrogen prevents T cell activation in part by directly blunting antigen 
presentation and in part via repression of IL-7 and IFN-γ production. This effect is amplified 
by the upregulation of the IL-7 suppressor TGF-β. The net result of these actions is a decrease in 
the number of TNF-producing T cells. The blunted levels of TNF diminish RANKL-induced OC 
formation, ultimately preventing bone loss. 
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Table 1: Benefits and risk of long term hormone replacement therapy in postmenopausal 
women (Perrie Delmas, 2002) 
Degree of evidence Benefits Risks 
Strong Relief of menopausal symptoms, 
Prevention of bone loss 
Vaginal bleeding, 
Breast tenderness ,Deep 
vein thrombosis 
and pulmonary 
embolism 
Moderate Prevention of fractures Increased risk of breast 
cancer after long-term 
use 
Weak Primary prevention of 
chronic heart disease 
Improvement of cognitive 
function, and preventionof 
Alzeihmer’s disease 
Slight increased risk of 
endometrial cancer,  
Slight increased risk of 
ovarian cancer 
 
Selective Estrogen Receptor Modulators (SERMs) (Perrie Delmas, 2002) 
SERMs and other oestrogen analogues act as oestrogen agonists or antagonists, 
dependent on the target tissue.  
e.g., Tamoxifen, Raloxifene, 
 
 Tamoxifen, which has long been used as an adjuvant treatment in breast cancer, is an 
oestrogen antagonist in breast tissue but a partial agonist in bone, cholesterol metabolism, 
and the endometrium. Tamoxifen does not wholly prevent bone loss in postmenopausal 
women but it does increase the risk of endometrial cancer, precluding its widespread use 
in healthy postmenopausal women. 
 
 Raloxifene, is a benzothiophene that competitively inhibits the action of oestrogen in the 
breast and the endometrium, and that acts as an oestrogen agonist on bone and lipid 
metabolism. In early postmenopausal women, raloxifene prevents postmenopausal bone 
loss at all skeletal sites, reduces markers of bone turnover to premenopausal 
concentrations, and reduces serum cholesterol concentration and its LDL fraction without 
stimulating the endometrium. Results of the MORE study (Multiple Outcomes of 
Raloxifene Evaluation), which involved 7705 women with osteoporosis, indicate that a 
30% and 50% reduction of incident vertebral fractures in women with and without 
prevalent vertebral fractures, respectively, happens after treatment with 
raloxifene. However, no effects on non-vertebral fractures were noted (table). In the 
MORE study, raloxifene also lowered the frequency of breast cancer by 70%. Raloxifene, 
can result in a reduction in coronary heart disease in the high-risk population of 
postmenopausal women as shown in the MORE study. Raloxifene does not impair 
cognitive function in postmenopausal women and might even slow age-related cognitive 
deterioration; raloxifene-treated women did better than controls in two tests of verbal 
memory and attention. Although rare, thromboembolic disease (venous thrombosis and 
pulmonary embolism) is increased in individuals treated with raloxifene, with a relative 
risk similar to that seen in those who take HRT. 
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Bisphosphonates (Perrie Delmas, 2002) 
Bisphosphonates are stable analogues of pyrophosphate characterised by a phosphorus-
carbon-phosphorus (P-C-P) bond. By substituting for hydrogens on the carbon atom,various 
bisphosphonates have been synthesised, the potency of which depends on the length and 
structure of the side chain. Bisphosphonates have a strong affinity for bone apatite, which is the 
basis for their clinical use. They are potent inhibitors of bone resorption, reducing the 
recruitment and activity of osteoclasts and increasing their apoptosis through a molecular 
mechanism recently identified. The oral bioavailability of bisphosphonates is low, between 1% 
and 3% of the dose ingested, and is impaired by food, calcium, iron, coffee, tea, and orange 
juice. These drugs are quickly cleared from plasma, with about 50% deposited in bone and 50% 
excreted in urine. The half-life of bisphosphonates in bone is several years. The safety profile of 
bisphosphonates is favourable; mild to moderate gastrointestinal discomfort that rarely results 
in discontinuation of medication has been reported for all (dyspepsia, abdominal pain, 
diarrhoea). 
e.g., alendronate, etidronate, risedronate, clodronate 
Calcitonin (Perrie Delmas, 2002) 
Calcitonin, a peptide produced by thyroid C cells, reduces bone resorption by direct 
inhibition of osteoclast activity. When given subcutaneously or intramuscularly, tolerance is 
sometimes poor (nausea, facial flushes, diarrhoea), whereas intranasal administration of salmon 
calcitonin 
has no significant side-effects. The minimum intranasal dose needed for a significant effect on 
BMD is 200 IU daily. Calcitonin is less effective in prevention of cortical bone loss than 
cancellous bone loss in postmenopausal women. 
 
Parathyroid hormone (PTH) (Perrie Delmas, 2002) 
Excess secretion and continuous intravenous infusion of PTH result in increased bone 
resorption and bone loss. By contrast, there is compelling evidence, in a range of species made 
osteoporotic by gonadectomy, that intermittent PTH injection restores bone strength by 
stimulation of new bone formation at the periosteal (outer) and endosteal (inner) bone surfaces, 
thickening the cortices and existing trabeculae of the skeleton, and perhaps increasing trabecular 
numbers and their connectivity. 
 
Other treatments (Perrie Delmas, 2002) 
Alfacalcidol and calcitriol are vitamin D analogues and are used in some countries for the 
treatment of osteoporosis. Both compounds induce a small increase in BMD that seems to be 
limited to the spine 
 
Non-Pharmacological Intervention (Perrie Delmas, 2002) 
 
 Nutrition 
 Exercise 
 Orthopaedic Management of Fractures 
 Other measures 
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Nutrition 
Good nutrition and a balanced diet with adequate caloriesare important for normal 
growth. Calcium is the most important nutrient for attaining adequate peak bone mass, 
but there is no universal consensus about the daily calcium requirement by age. The 1994 
consensus development conference on optimum calcium intake recommended 1200–1500 mg 
daily for adolescents, 1000 mg daily for adults up to age 65 years, and 1500 mg daily for 
postmenopausal women not receiving oestrogen and for elderly people. A recent National 
Institute of Health panel has reinforced the importance of adequate calcium intake. Although 
results of most studies indicate a beneficial effect of calcium supplementation, the longterm 
effect of a high dietary calcium intake on bone health is unclear. Conversely, there seems to be a 
threshold of calcium intake, around 400 mg per day, below which increasing calcium intake 
seems beneficial and necessary, both in children and in women older than age 60 years. Vitamin 
D is essential for the intestinal absorption of calcium and, as discussed above, serum 
concentrations of 25-hydroxyvitamin D decline with age. Findings of several studies suggest that 
the daily intake of vitamin D should be around 400–800 IU if sunlight exposure is low. An 
adequate protein intake is essential in frail elderly individuals. 
 
Exercise: 
Physical activity early in life contributes to high peak bone mass. Various activities, 
including walking, weight training, and high impact exercises, induce a small (1–2%) increase in 
BMD at some but not all skeletal sites, that is not sustained once the exercise programme is 
stopped. Fitness might indirectly protect individuals from fractures by improving mobility and 
muscle function, and by reducing the risk of falls. Findings of observational studies suggest that 
regular 
exercise and recreational activity reduce hip and leg fracture risk but increase the risk of wrist 
fracture. After a vertebral fracture, a supervised exercise programme to maintain strength and 
flexibility of the thoracic and lumbar spine is recommended in elderly individuals. 
 
Orthopaedic management of fractures: 
Early surgical management of hip fractures is essential to decrease mortality rate and to 
improve perioperative morbidity, which is pronounced—especially in frail elderly individuals. 
The surgical treatment of peripheral fragility fractures does not require specific procedures, since 
the rate at which fracture heals is much the same in patients of a similar age with and without 
osteoporosis. In patients with major pain related to a crushed vertebra, vertebral plasty, involving 
injection of polymetalmetacrylate cement into the vertebral body, has been suggested. Although 
this procedure might have a beneficial effect on acute pain, the long-term effects on the 
subsequent risk of fractures of adjacent vertebrae have not been assessed. 
 
Other measures 
Treatments that predispose to osteoporosis e.g., chronic corticosteroid therapy should be 
avoided whenever possible. In addition to an exercise programme, a strategy to decrease the risk 
of falls in elderly individuals should be implemented. Visual impairment and cataract should be 
detected and treated and whenever possible, the use of drugs that increase the risk of falling e.g., 
benzodiazepine, hypnotics, antidepressants, and medications that induce hypotension should be 
reduced. Furthermore, patients should be instructed to avoid slippery floors and install adequate 
lighting at home. Finally, results of two controlled studies done in elderly individuals in care 
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homes have shown that the risk of hip fracture could be reduced as much as 50% by use of 
energy-absorbing external hip protectors. However, long-term adherence with these devices is 
unknown. 
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RALOXIFENE HYDROCHLORIDE  
PHYSIOCHEMICAL PROPERTIES                         
Structure (Wishart et al., 2006): 
    
Molecular formula  : C28H27NO4S. HCl (Medicines and Healthcare products 
                                                                                               Regulatory Agencies, 2013). 
Molecular weight  : 510.0 (MHRA, 2013). 
Chemical Name                  : [6-Hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl][4-[2-
(piperidin-1-yl)ethoxy]phenyl]methanone hydrochloride 
(MHRA, 2013). 
CAS Number   : 82640-04-8 (MHRA, 2013). 
Category      : A second generation selective oestrogen receptor modulator      
                                                  (SERM) used to prevent and treat osteoporosis in postmenopausal  
                                                  women. It has estrogen agonist action on bone and cholesterol  
                                                  metabolism but behaves as a complete antagonist on mammary 
                                                  gland and uterine tissue (Wishart et al., 2006). 
Description : Almost white or pale-yellow powder (MHRA, 2013). 
Solubility   : Freely soluble in dimethylsulphoxide, sparingly soluble in  
                                                  methanol, slightly soluble in ethanol, very slightly soluble in 
                                                  water and isopropyl alcohol and practically insoluble in ether and 
                                                  ethyl acetate (Ministryof Health and Family Welfare, 2014). 
Storage      : Store protected from moisture (ASHP, 2011). 
Melting point                         : 258
o
C (Jo Watts et al., 2011). 
 
INDICATION
 
For the prevention and treatment of osteoporosis in postmenopausal women (ASHP, 
2011)
 
Drug Profile 
 
Department of Pharmaceutics, Madras Medical College Page 28  
  
 
DOSE 
60mg once daily (ASHP, 2011) 
 
PHARMACOKINETICS (ASHP, 2011) 
 Absorption: Raloxifene hydrochloride is rapidly absorbed from the GI tract. Because 
raloxifene undergoes extensive first-pass glucuronidation, oral bioavailability of 
unchanged drug is low. While approximately 60% of an oral dose is absorbed, absolute 
bioavailability as unchanged raloxifene is only 2%. However, systemic availability of 
raloxifene may be greater than that indicated in bioavailability studies because circulating 
glucuronide conjugates are converted back to parent drug in various tissues. 
 Protein Binding: Raloxifene and its monoglucuronide conjugates are more than 95% 
bound to plasma proteins. Raloxifene binds to albumin and α1-acid glycoprotein, but not 
to testosterone-estradiol binding globulin (sex hormone binding globuli 
 Metabolism: Hepatic, raloxifene undergoes extensive first-pass metabolism to the 
glucuronide conjugates: raloxifene-4’-glucuronide, raloxifene-6-glucuronide, a 6, 4’-
diglucuronide. No other metabolites have been detected, providing strong evidence that 
raloxifene is not metabolized by cytochrome P450 enzymes. 
 Elimination T1/2: 27.7hr 
 Route of elimination: Raloxifene is primarily excreted in feces, and less than 0.2% is 
excreted unchanged in urine. 
 Volume of distribution: 2348L/kg (oral administration of single doses rangin from 30 to 
150mg) 
 Clearance: Apparent oral clearance of the drug is 44.1L/kg.hr 
 
PHARMACODYNAMICS (ASHP, 2011) 
 Prevention and treatment of osteoporosis in postmenopausal women 
 Prevention or treatment of corticosteroid-induced hypogonadism and osteoporosis 
 Reduction in the incidence of breast cancer 
Prevention and treatment of osteoporosis in postmenopausal women: 
             Osteoporosis, a systemic skeletal disease characterized by low bone mass and 
microarchitechtural deterioration of bone tissue with consequent increased bone fragility and 
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susceptibility to fracture, is  observed in a large proportion of 3postmenopausal women. Adult 
women have less bone mass than men at all ages, and decreased production of estrogen at 
menopause is associated with accelerated bone loss, particularly from the lumbar spine , for 
about 5 years, during which skeletal mass loss averages 3% per year. While the risk of 
postmenopausal osteoporosis is associated with many risk factors including premature ovarian 
failure; a family history of osteoporosis; a small, slim body frame; endocrine disorders such as 
thyrotoxicosis, hyperparathyroidism, cushing’s syndrome, hyperprolactinemia, and insulin-
dependent diabetes mellitus (type I, IDDM); cigarette smoking, drinking excessive amounts of 
alcohol; a sedentary life style and/or lack of physical exercise; low body weight; and low dietary 
calcium intake. Premature ovarian failure (surgical or nonsurgical) hastens the onset of 
osteoporosis, and estrogen deficiency in premenopausal women induces bone loss and may 
reduce peak bone mass. 
              Raloxifene is used for the treatment of postmenopausal osteoporosis. Estrogen 
replacement therapy is effective for the treatment of osteoporosis in postmenopausal women and 
has recommended as first line therapy for women with osteoporosis. However, because results of 
a recent controlled study indicate that estrogen/ progestin therapy is associated with a small 
increase in the risk of breast cancer, cardiovascular disease, stroke, and venous 
thromboembolism, recommendations on appropriate use of such therapy are being revised. Other 
therapeutic modalities for the treatment of osteoporosis include alendronate, calcitonin, calcium, 
risedronate, and vitamin D. Therapy, with alendronate reduces spine and nonspine fracturerates 
in women with osteoporosis. While recent evidence indicates that raloxifene reduces the risk of 
vertebral fracture in women with osteoporosis. 
Prevention or treatment of corticosteroid-induced hypogonadism and osteoporosis: 
              Patients receiving long-term corticosteroid therapy may develop hypogonadism 
secondry to inhibition of secretion of leutinizing hormone (LH) and follicle stimulating hormone 
(FSH) from the pituitary as well as secondary to direct effects on the ovaries and testes, and such 
hypogonadism may be associated with bone loss. Hormone Replacement therapy (combined 
estrogen and progestin therapy) has been effective in increasing bone mass density (BMD) in 
postmenopausal women with asthma or rheumatoid arthritis who were receiving corticosteroid 
therapy. Although the efficacy of raloxifene for the prevention or treatment of corticosteroid-
induced bone loss remains to be established, some experts (e.g., the American College of 
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Rheumatology) currently state that raloxifene theoretically should be effective in preventing such 
bone loss and therefore can be offered to selected postmenopausal corticosteroid-treated women 
who refuse HRT therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in 
whom such therapies are contraindicated. 
Reduction in the incidence of breast cancer: 
                Raloxifene is used to reduce the incidence of invasive breast cancer in postmenopausal 
women with osteoporosis and in postmenopausal women at high risk of developing invasive 
breast cancer. Raloxifene should not be used to reduce the risk of breast cancer in premenopausal 
women. 
                Raloxifene is not indicated for the treatment of breast cancer or to reduce the risk of 
recurrence of breast cancer. Raloxifene is not indicated for reduction in the risk of noninvasive 
breast cancer. 
MECHANISM OF ACTION 
                Raloxifene is a selective estrogen receptor modulator (SERM) with mixed estrogen 
agonist or antagonist (antiestrogen) activity in specific tissues. Raloxifene exhibits estrogen 
agonist activity on bone and circulating lipoproteins, but estrogen antagonist activity on breast 
and uterine tissues. Estrogens have an important role in the reproductive, skeletal, 
cardiovascular, and central nervous system in women, and act principally by regulating gene 
expression (ASHP, 2011)  
There are three interactive mechanism that explain the pharmacology of SERMs: 
 Differential estrogen-receptor expression in a given target tissue,  
 Differential estrogen-receptor conformation on ligand binding and  
 Differential expression and binding to the estrogen–receptor of coregulator proteins .  
There are two main types of estrogen receptors α and β. The α-receptor is mainly an activator 
and β-receptor inhibitor. The SERMs bind to both receptors, functioning as pure antagonist when 
binding to β-receptors and as a partial agonist when binding to the α-receptor. The different 
action of individual SERM depends on coregulatory proteins and their ability to recruit 
coactivators. Estrogenic activation inhibits osteoclasts and thereby reduces the bone resorption 
by osteoclasts that  restores the balance between bone formation and bone resorption (Helga 
Hansdottir, 2008). 
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ADVERSE EFFECT (Helga Hansdottir, 2008) 
                  The increased incidence of venous thromboembolism is the main concern of 
raloxifene therapy and previous history of venous thromboembolism is contraindication for use 
of raloxifene.  
 
DRUG INTERACTIONS (ASHP, 2011) 
 Colestyramine reduces the absorption and enterohepatic cycling of raloxifene, and 
they should not be given together. 
 Concomitant administration of single doses of raloxifene and warfarin has resulted in 
a 10% decrease in prothrombin time compared with administration of warfarin alone . 
In raloxifene-treated women with ospeoporosis, concomitant administration of 
warfarin did not affect the plasma concentrations of raloxifene. If the drugs are used 
concomitantly, the patient and prothrombin time should be monitored closely and the 
dosage of the anticoagulant adusted accordingly  
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PLURONIC F127
 
1. Synonyms: 
   Poloxamer 407, Synperonic PE/F 127 (Badische Anilin – und Soda – Fabrik Corporation, 
n.d.) 
2. Chemical Name:  
Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (BASF 
Corporation, n.d.) 
 
3. Structure (BASF Corporation, n.d.): 
 
4. Molecular weight:   
Molecular weight approximately 12,600 daltons (Diego Chiapetta & Alejandro Sosnik, 
2007)  
5. Functional category (Raymond Rowe et al., 2009):  
Fat emulsifier, 
Flavour solubilizer, 
Fluorocarbon emulsifier, 
Gelling agent, 
Spreading agent, 
Stabilizing agent, 
Suppository base, 
Tablet coating, 
Tablet excipient and 
Wetting agent. 
6. Properties: 
 
Melting point:   52-57
o
C (BASF Corporation, n.d.) 
           Description:  Hydrophilic non-ionic surfactant of the more general class  of copolymers 
known as Poloxamers. Its surfactant properties are dependent on the 
hydrophilic (EO) / hydrophobic (PO) ratio. High EO content gives better 
O
/W  stabilizers (BASF Corporation, n.d.). 
 Total average number of EO units: 200.5 (Diego Chiapetta & Aljendro Sosnik, 2007) 
 Total average number of PO units: 65.2 (Diego Chiapetta & Aljendro Sosnik, 2007) 
           CMC: 0.004 – 0.60%w/w (BASF Corporation, n.d.) 
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HLB: 22 (BASF Corporation, n.d.) 
 
7. Applications (BASF Corporation, n.d.): 
   Pluronic
 
F127 was used to coat a siliconized coverslip to hold an egg extract in a study. 
Pluronic F127 was added to phosphate buffered saline (PBS), to lower unspecific cell and 
protein adhesion to a PDMS-based microfluidic device. A study reports its use as a release 
vehicle to transport low-dose perivascular lipopolysaccharide (LPS) on mouse vein grafts. 
PLGA/pluronic F127 may be used to fabricate nerve guidance conduits (NGCs) for 
regeneration of peripheral nerve. Fabrication of poly (lactide-co-glycolide) (PLGA) — 
Pluronic F127 glass composites was reported. Pluronic F-127 was used for fluorescent 
labeling of blood vessels, astrocytes, and neurons 
 
PLURONIC L121
 
1. Chemical Name (BASF Corporation, n.d.):  
 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) 
 
2. Structure (BASF Corporation, n.d.): 
 
 
3. Molecular weight:   
Molecular weight approximately 4,400 daltons ( Diego Chiapetta & Alejandro Sosnik, 
2007). 
 
4. Functional category (Raymond Rowe et al., 2009):  
Fat emulsifier, 
Flavour solubilizer, 
Fluorocarbon emulsifier, 
Gelling agent, 
Spreading agent, 
Stabilizing agent, 
Suppository base, 
Tablet coating, 
Tablet excipient and 
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Wetting agent. 
 
5. Properties:  
Surface tension:   33 dyn/cm; 25
o
C, 0.1wt%in H2O (BASF Corporation, n.d.) 
           Description: Colorless viscous liquid, surface active material whose properties are   
                               dependent on the hydrophilic (EO) / hydrophobic (PO) ratio. High EO  
                               content gives better 
O
/W stabilizers (BASF Corporation, n.d.).   
Total average number of EO units: 10.0 (Diego Chiapetta & Aljendro Sosnik, 2007) 
 Total average number of PO units: 68.3 (Diego Chiapetta & Aljendro Sosnik, 2007)                                                                                                                                                                                                                                                                                                 
           CMC: 0.0004 – 0.005%w/w (BASF Corporation, n.d.) 
HLB: 1 (BASF Corporation, n.d.) 
6. Applications (BASF Corporation, n.d.): 
   A non-ionic copolymer surfactant qualified for use in insect cell culture, applications as 
an antifoaming agent. 
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The list of drug, excipients used and their manufacturer are shown in Table 2 
 
 
 
Table 2: List of Materials Used   
S.No. DRUG/EXCIPIENT MANUFACTURER 
1 Raloxifene Hydrochloride Orchid Chemicals and Pharmaceuticals 
Ltd. 
2 Pluronic L121 Sigma-Aldrich Chemicals Pvt. Ltd., USA 
3 Pluronic F127 Sigma-Aldrich Chemicals Pvt. Ltd., 
Germany 
4 Methanol Finar limited 
5 Tween 80 Scientific Chemicals 
6 Potassium dihydrogen ortho phosphate Thermo Fisher Scientific India Pvt. Ltd. 
7 Sodium Hydroxide Indian Research Products 
8 Sucrose Thermo Fisher Scientific India Pvt. Ltd. 
9 Dialysis Membrane 110 Himedia 
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The list of equipments used in the study and their manufacturer are shown in Table 3. 
Table 3: List of Equipments 
S.No. EQUIPMENTS MANUFACTURER 
1 Rotary flash evaporator Equitron 
2 Ultra Sonicator Lark 
3 Electronic balance Model No – Jewel – 3 Eagle 
4 UV-Visible 
Spectrophotometer 
SHIMADZU                                
UV – 1800 
5 Magnetic stirrer with hot 
plate 
Eltek Magnetic Stirrers 
6 Malvern zeta sizer Malvern, Germany 
7 Super-Resolution and 
Confocal Microscopy ( Zeiss 
ELYRA PS. 1) 
Carl Zeiss Microscopy GmbH, 
jena, Germany 
8 FT-IR Spectrophotometer Nicolet, India 
9 VirTis Advantage Plus 
Benchtop Freeze Dryer 
SP Scientific 
10 Refrigerator Whirlpool 
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METHODOLOGY 
PREPARATION OF PHOSPHATE BUFFER pH 6.8  
                    27.218g of potassium dihydrogen phosphate is dissolved in 1 litre of distilled water 
to give 0.2M solution, 8g of sodium hydroxide is dissolved in one litre of distilled water to give 
0.2M solution. 500ml of 0.2M potassium dihydrogen phosphate and 224ml of 0.2M sodium 
hydroxide solutions are mixed together and made upto 2 litres with distilled water (MOHFW, 
2014). 
 
DRUG EXCIPIENT COMPATIBILITY STUDIES (Gurdeep Chatwal and Sham Anand, 
2002)  
Infrared spectroscopy can be used to identify a compound and also to investigate the composition 
of the mixture. Pure drug and Drug-Excipient mixtures were subjected to FT-IR to investigate 
the Drug-Excipient interactions. The IR spectra of the test samples were obtained by Pressed 
Pellet Technique using Potassium bromide. 
Potassium bromide pellet method 
A small amount of finely ground solid sample was intimately mixed with about 100 times of its 
weight of powdered Potassium bromide. The finely ground mixture was then passed under high 
pressure in a press (at least 25,000 psig) to form a small pellet (about 1-2 mm thick and 1 cm in 
diameter). The resulting pellet was placed in the sample cell and the spectra were recorded. 
 
STANDARD CURVE FOR RALOXIFENE HYDROCHLORIDE (RXH)  
                    100mg of Raloxifene Hydrochloride was accurately weighed and dissolved in a 
small quantity of methanol and made upto 100ml with methanol. From this primary solution, 
10ml was pipette out and made up to 100ml with phosphate buffer pH 6.8. From this secondary 
solution aliquots were taken to produce concentration of 2, 4, 6, 8 and 10 µg/ml. The absorbance 
of the resulting solution was measured at 285nm in UV- Visible Spectrophotometer (Shimadzu) 
using phosphate buffer pH 6.8 as blank. The standard curve was plotted taking concentration in 
X-axis and absorbance in Y-axis (Anand Kumar Kushwaha et al., 2013) 
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FORMULATION OF RALOXIFENE HYDROCHLORIDE POLYMERIC MICELLES 
                     The RXH loaded mixed pluronic polymeric micelles were prepared by film 
rehydration method. Accurately weighed quantities of RXH, Pluronic L121 and Pluronic F127 
were dissolved in sufficient quantity of methanol to give a clear solution. The resulting solution 
is poured into a 1000ml rotary flask and evaporated under vacuum at room temperature for 2 
hours to yield the L121/F127 matrix film. Distilled water was added to the matrix film to obtain 
1%
w
/w fraction of Pluronic F127 and Pluronic L121; and 1%w/w fraction of either polymer. The 
round bottom flask was gently rotated for 1 hour at 30 – 40oC. The resulting polymeric 
L121/F127 micelle dispersions were allowed to equilibrate at room temperature for 24 hours 
followed by sonication with ultrasonicator for 2 mins and then the optimized micellar dispersion 
is concentrated with the help of lyophilizer using cryoprotective agent, sucrose (2.5%
w
/w) (Ivan 
Pepic et al., 2014). 
Table 4: Formulation Code of  L121/F127 micelle dispersions  
FORMULATION 
CODE 
DRUG 
(RALOXIFENE 
HYDROCHLORIDE) 
(mg) 
PLURONIC 
L121 
(mg) 
PLURONIC 
F127 
(mg) 
WATER 
added to 
produce 
F-1 60 170 500 1%
w
/w 
fraction of  
F127 
F-2 60 250 500 1%
w
/w 
fraction of 
F127 
F-3 60 500 170 1%
w
/w 
fraction of 
L121 
F-4 60 500 250 1%
w
/w 
fraction of 
L121 
F-5 60 300 300 1%
w
/w 
fraction of 
L121 and 
F127 
F-6 60 500 500 1%
w
/w 
fraction of 
L121 and 
F127 
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CHARACTERIZATION OF POLYMERIC L121/F127 MICELLE DISPERSIONS 
ENTRAPMENT EFFICIENCY (Liyan Zhao et al., 2012)
 
                The concentration of RXH in the micelles were determined with UV-Vis 
Spectrophotometer (UV-1800, Shimadzu) at 285nm. The micelles were lysed using 15ml of 
methanol and the concentration was determined using UV-Vis Spectrophotometer after suitable 
dilution. The percentage of drug entrapment in micelle dispersions was calculated using the 
following formula, 
EE%=          Weight of the drug in the micelles         ×100    
                Weight of the feeding polymer and drug             
IN-VITRO DIFFUSION STUDY  
                 In-vitro release studies werer performed using pH 6.8 phosphate buffer containing 
0.5%
v
/v polysorbate 80 by dialysis bag method using dialysis membrane having molecular 
weight cut off 12,000- 14,000 daltons. Micelle dispersions was filled into a dialysis membrane 
bag and tied at both the ends and placed in a 1000ml beaker containing 900ml of diffusion 
medium; temperature and speed were maintained at 37
o
C and 100rpm, respectively using 
magnetic stirrer. 5 ml of samples were collected at a predetermined time and replenished with the 
same volume of fresh buffer to maintain the sink condition. Samples were analyzed at 285nm 
UV spectrophotometrically (Anand Kumar Kushwaha et al., 2013). 
KINETICS OF DRUG RELEASE (Brahmankar and Sunil Jaiswal, 2009)
 
Various models were tested for explaining the kinetics of drug release. To analyze the 
mechanism of the drug release rate kinetics of the dosage form, the obtained data were plotted in 
various kinetic models (Zero-order, First order, Higuchi, Hixson-Crowell release model and 
Korsmeyer-Peppas release model). 
1. Zero order equation 
The zero order release can be obtained by plotting cumulative % percentage drug release 
versus time. It is ideal for the formulation to have release profile of zero order to achieve 
pharmacological prolonged action. 
C=K0t 
Where, K0 = Zero order constant 
 t = Time in hours 
2. First order equation 
The graph was plotted as log % cumulative drug remaining Vs time in hours. 
     Log C= log C0 - Kt/2.303 
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Where, C0 = Initial concentration of drug 
 K = First order 
   t = Time in hours 
3. Higuchi kinetics 
The graph was plotted with % cumulative drug released vs. square root of time 
Q = Kt
½
 
Where, K= constant reflecting design variable system (differential rate constant) 
 t = Time in hours 
4. Hixon and Crowell erosion equation 
To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixon and Crowell rate equation. The graph was plotted 
by cube root of % drug remaining vs. time in hours. 
Q0
1/3
 – Qt
1/3
 = KHCXt 
Where, Qt = amount of drug released in time t. 
 Q0 = Initial Amount of drug 
KHC= Rate constant for Hixon Crowell equation 
5. Korsmeyer-Peppas equation 
To evaluate the mechanism of drug release, it was further plotted in Peppas equation as 
log cumulative % of drug released Vs.log time. 
Mt/Mα = Kt
n
 
Where, Mt/Mα = Fraction of drug released at time t 
 t = Release time 
 K=Kinetics constant (Incorporating structural and geometric characteristics of  
the formulation) 
 n = Diffusional exponent indicative of the mechanism of drug release. 
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Table 5: Diffusion mechanism is given by the slope (n) value, 
n value Mechanism 
0.45 Fickian diffusion 
0.45 <  n  <  0.89 Anomalous (non- Fickian) diffusion 
0.89 Case II transport 
n > 0.89 Super case II transport 
The models were used to analyze the release of pharmaceutical polymeric dosage forms when 
the release mechanism was not known or more than one type of release was involved. The r
2
 and 
K values were calculated for the linear curve obtained by regression analysis of the above plots 
PARTICLE SIZE ANALYSIS 
               The micelle dispersion was diluted, filled in a cuvette using suitable blank and the 
average size and polydispersity index (PDI) was determined using Malvern zeta sizer 
(Samyuktha Rani & Vedha Hari, 2011). 
POLYDISPERSITY INDEX 
The term polydispersity is used to describe the degree of “non –uniformity” of a distribution 
(material talks). The Polydispersity index as a measure of the width of molecular weight 
distribution (MWD) (Ulf Nobbman, 2014). 
Table 6: Polydispersity Index (Ryan Shaw, n.d.) 
POLYDISPERSITY INDEX 
VALUE (PDI) 
COMMENTS 
<0.05 Monodisperse sample. 
<0.08 Nearly monodisperse sample. 
0.08 to 0.7 Mid-range value of PDI. It is the range over which the 
distributions algorithms best operate. 
>0.7 Indicates a very broad distribution of particle size 
 
ZETA POTENTIAL ANALYSIS (Ye Jin et al., 2013) 
           Zeta potential analysis was used to measure the stability of micelle dispersions by 
studying its colloidal property. Aggregation is attributed to the shielding of the micelle surface 
charge by ions in the solution and thereby reducing the electrostatic repulsion. Micelle surface 
charge can be estimated by measurement of particle electrophoretic mobility and is expressed as 
the zeta potential. The study was conducted using Malvern Zeta Analyzer 
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SOLUBILITY STUDIES 
Solubility study of Raloxifene Hydrochloride  
An excess amount of drug is added to the distilled water and then left until equilibrium is 
established for 72 hrs at room temperature with occasional stirring. Then filtered and the filterate 
is suitably diluted with phosphate buffer pH 6.8 and analyzed using UV-Visible 
spectrophotometer at 285nm. The concentration is considered is considered the saturation or 
equilibrium solubility of drug (Ramy Elsergany, 2014). 
Solubility study of optimized formulation 
 The optimized formulation is filtered and the filterate is suitably diluted with phosphate 
buffer pH 6.8 and analyzed using UV-Visibe spectrophotometer at 285 nm (Carlota Rangel – 
Yagui et al., 2013). 
SUPER-RESOLUTION AND CONFOCAL MICROSCOPY (Samuel G.L., 2017) 
          The morphology of micelle dispersions were measured by super resolution and confocal 
microscopy. A small amount of the sample is placed in the mounting medium (Prolong Gold) on 
the slide. Cover slip is placed over the sample with a spacer and with the help of nail polish it is 
sealed and let dried. After which, using zen software, high resolution 2D and 3D fluorescence 
images were established.  
LYOPHILIZATION OF THE L121/F127 MICELLES (Ivan Pepic et al., 2014) 
           The micelles were prepared using the film rehydration method with ultrasonication. The 
preparation which yielded best results were selected for the freeze-drying process. 
            2.5%
w
/w of sucrose is added as cryoprotective agent to micelle dispersions. After which, 
aliquots of the L121/F127 micelle dispersions are transferred to freeze-drying flask. The samples 
were frozen by rotating the flask in a bath called a shell freezer which is cooled by mechanical 
refrigeration at -70
o
C for 3 hours. After freezing, the micelle dispersions were uncapped and 
transferred into a -53
o
C pre-equilibrated chamber of an VirTis Advantage Plus Benchtop Freeze 
Dryer (SP Scientific) which was depressurized using a vacuum pump. The temperature was 
maintained at -53
o
C during the 24h of primary drying and the concentrated dispersion was 
removed after reestablishing ambient pressure, the vials were capped and stored at 2 to 8
o
C until 
further use. 
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DRUG EXCIPIENT COMPATIBILITY STUDIES 
The possible interaction between the drug and the excipients used in the formulation was 
studied by FTIR spectroscopy. The results are given in the below 
 
FTIR SPECTRA OF DRUG (RALOXIFENE HYDROCHLORIDE) 
 
 
Fig. 5: FT–IR spectra of Raloxifene Hydrochloride 
 
Table 7: Interpretation 
 
 
 
 
 
S.No. WAVENUMBER (cm
-1
) CHARACTERISTICS 
1 2954.73 C-H stretching 
2 1643.23 C=C stretching 
3 1465.79 O-H bending 
4 948.91 C-O stretching 
5 833.19 C-C stretching 
6 702.04 N-H rocking 
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FTIR SPECTRA OF RALOXIFENE HYDROCHLORIDE WITH PLURONIC F127 
 
 
Fig. 6: FT–IR spectra of Raloxifene Hydrochloride with Pluronic F127 
Table 8: Interpretation 
  
 
 
 
 
 
The peaks observed in the FTIR spectrum showed no shift and no disappearance of 
characteristic peaks of drug. This suggests that there was no interaction between the drug and 
Pluronic F127 (Gurdeep Chatwal and Sham Anand, 2002). 
S.No. WAVENUMBER (cm
-1
) CHARACTERISTICS 
1 2954.73 C-H stretching 
2 1643.23 C=C stretching 
3 1434.93 O-H bending 
4 948.91 C-O stretching 
5 833.19 C-C stretching 
6 702.04 N-H rocking 
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FTIR SPECTRA OF RALOXIFENE HYDROCHLORIDE WITH PLURONIC L121 
 
 
Fig. 7: FT–IR spectra of Raloxifene Hydrochloride with Pluronic L121 
Table 9: Interpretation 
 
 
 
 
 
 
The peaks observed in the FTIR spectrum showed no shift and no disappearance of 
characteristic peaks of drug. This suggests that there was no interaction between the drug and 
Pluronic L121 (Gurdeep Chatwal and Sham Anand, 2002). 
 
S.No. WAVENUMBER (cm
-1
) CHARACTERISTICS 
1 2970.16 C-H stretching 
2 1643.23 C=C stretching 
3 1458.08 O-H bending 
4 933.48 C-O stretching 
5 833.19 C-C stretching 
6 702.04 N-H rocking 
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FTIR SPECTRA OF RALOXIFENE HYDROCHLORIDE WITH PLURONIC F127 AND L121 
 
 
Fig. 8: FT–IR spectra of Raloxifene Hydrochloride with Pluronic F127 and L121 
Table 10: Interpretation 
 
 
 
 
 
 
The peaks observed in the FTIR spectrum showed no shift and no disappearance of 
characteristic peaks of drug. This suggests that there was no interaction between the drug and drug 
loaded polymeric micelles (Gurdeep Chatwal and Sham Anand, 2002). 
 
 
S.No. WAVENUMBER (cm
-1
) CHARACTERISTICS 
1 2970.16 C-H stretching 
2 1643.23 C=C stretching 
3 1465.79 O-H bending 
4 948.91 C-O stretching 
5 840.90 C-C stretching 
6 702.04 N-H rocking 
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STANDARD CURVE OF RALOXIFENE HYDROCHLORIDE 
 The UV spectrophotometric method was used to analyse Raloxifene Hydrochloride. The 
absorbance of the drug in phosphate buffered saline pH6.8 was measured at a wavelength of 
285nm. The results are given in  the following table and figure 
Table 11: Data for Calibration Curve of Raloxifene Hydrochloride 
S. No. Concentration (µg/ml) Absorbance at 285 nm 
1 2 0.104±0.00294 
2 4 0.233±0.00169 
3 6 0.341±0.01228 
4 8 0.449±0.01806 
5 10 0.563±0.01673 
*Mean± SD (n=3) 
 
 
Fig. 9: Standard Curve of Raloxifene Hydrochloride in PBS pH 6.8 
 
The standard curve of Raloxifene Hydrochloride in PBS pH6.8 was linear in 2 to 10µg/ml 
concentrations , starting from origin. The curve obeys Beer Lambert’s law (Gurdeep Chatwal & 
Sham Anand, 2002). 
y = 0.0565x - 0.001 
R² = 0.9994 
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CALIBRATION CURVE FOR RALOXIFENE HYDROCHLORIDE IN 
PHOSPHATE BUFFER pH 6.8  
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CHARACTERIZATION OF MICELLAR DISPERSIONS 
 ENTRAPMENT EFFICIENCY 
Table 12 : Entrapment efficiency of Raloxifene Hydrochloride loaded micellar dispersions 
FORMULATION 
CODE 
% ENTRAPMENT 
EFFICIENCY 
(% w/w) 
F-1 94.75 
F-2 95.00 
F-3 94.16 
F-4 92.50 
F-5 95.50 
F-6 95.83 
 
 
Fig. 10: Entrapment efficiency of Raloxifene Hydrochloride loaded micellar dispersions 
 
 The entrapment efficiency of all the formulations was between 92 to 96%. It was found 
to be 94.75, 95, 94.16, 92.5, 95.5 and 95.83% for F-1, F-2, F-3, F-4, F-5 and F-6 respectively. 
90 
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93 
94 
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96 
F-1 F-2 F-3 F-4 F-5 F-6 
% ENTRAPMENT EFFICIENCY 
% ENTRAPMENT 
EFFICIENCY 
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 IN-VITRO DIFFUSION STUDY 
  The in-vitro release study of Raloxifene Hydrochloride micellar dispersions were 
performed using pH 6.8 phosphate buffer containing 0.5%
v
/v polysorbate 80 by dialysis bag 
method using dialysis membrane having molecular weight cut off 12,000 – 14000 daltons. 
Table 13: In-vitro release of Raloxifene Hydrochloride loaded micellar dispersions 
Time (in 
hours) F-1 F-2 F-3 F-4 F-5 F-6 
0.5 14.58 9.27 0.78 2.13 5.58 1.59 
1 17.60 12.77 2.64 3.19 9.84 3.18 
1.5 19.28 15.24 4.009 5.33 11.75 5.60 
2 21.25 16.10 4.54 6.14 13.41 9.32 
3 22.69 17.27 5.37 6.72 14.29 9.37 
4 24.67 18.41 5.67 6.75 14.61 9.70 
5 26.66 19.32 5.70 7.06 15.77 10.02 
23 54.38 33.74 16.86 21.41 29.65 22.55 
24 57.59 34.19 17.5 22.07 30.32 22.95 
25 59.76 35.43 17.59 22.19 31.30 23.58 
26 61.67 36.43 18.47 22.85 32.25 23.71 
27 62.55 37.88 18.84 23.24 33.50 24.38 
28 63.93 38.42 19.21 23.44 34.46 24.78 
29 66.41 39.43 19.31 23.74 35.73 24.91 
47 77.92 59.26 29.77 - 48.91 37.50 
48 81.51 60.39 30.71 - 49.71 37.97 
49 85.40 61.76 31.41 - 49.97 38.17 
50 89.30 63.14 31.58 - 51.02 38.64 
51 92.14 64.29 32.02 - 52.1 39.12 
52 - 65.95 32.46 - 53.15 39.32 
53 - 67.10 32.90 - 54.27 39.8 
71 - 82.81 42.61 - 68.84 56.99 
72 - 84.84 42.84 - 69.74 57.29 
73 - 87.41 43.33 - 70.64 58.10 
74 - 89.19 44.07 - 71.79 58.41 
75 - 90.46 44.30 - 72.97 59.25 
76 - 91.47 45.07 - 74.13 59.56 
77 - 92.46 45.84 - 74.78 60.41 
95 - - - 62.59 86.84 70.53 
96 - - - 63.74 87.82 70.90 
97 - - - 64.36 89.06 71.53 
98 - - - 64.71 90.05 72.41 
99 - - - 65.6 - 72.78 
100 - - - 66.19 - 73.69 
101 - - - 66.54 - 74.06 
119 - - 65.16 77.51 - 89.04 
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Fig. 11: In-vitro release of Raloxifene Hydrochloride loaded micellar dispersions 
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120 - - 67.12 78.19 - 89.50 
121 - - 67.47 78.87 - 90.46 
122 - - 68.06 79.56 - 91.46 
123 - - 68.41 79.97 - - 
124 - - 69.03 80.90 - - 
125 - - 69.66 81.59 - - 
143 - - 78.50 88.64 - - 
144 - - 78.91 89.64 - - 
145 - - 79.58 90.64 - - 
146 - - 80.52 91.10 - - 
147 - - 81.17 - - - 
148 - - 81.85 - - - 
149 - - 82.26 - - - 
167 - - 89.03 - - - 
168 - - 89.74 - - - 
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 The cumulative % drug release at 29 hours is 66.41, 39.43, 19.31, 23.74, 35.73 and 
24.91%  for F-1, F-2, F-3, F-4, F-5 and F-6 respectively.  
 Increase in concentration of hydrophilic polymer resulted in release of drug (92.14 and 
92.46%) at 51 and 77 hours respectively for F-1 and F-2. 
 Increase in the concentration of hydrophilic polymer (pluronic F127) increase the PEO 
units leading to more hydrophilic channel and faster release of drug (Zhang Wei et al., 2009)  
 Increase in the hydrophobic polymer (pluronic L121) concentration, sustains the release 
of drug (Jaber Emami et al., 2015).  For eg: increase in pluronic L121 concentration shows release 
of drug (89.74 and 91.10%) at 168 and 146 hours respectively for F-3 and F-4. 
 The micellar dispersions with same ratio of L121/F127 shows release of drug (90.05 and 
91.46%) at 98 and 122 hours respectively for F-5 and F-6. 
 The hydrophobic core is essential and hydrophilic corona prevent recognition by the 
RES (Bhagwat and Vaidhya, 2013) and therefore preliminary elimination of the micelles from the 
blood stream, this may result in prolonged circulation. 
 Though increase in pluronic L121 concentration shows sustained release, the use of 
F127 is essential because it has longer PEO units. Thus using the same ratio of both L121 and F127 
may result in prolonged circulation as micelles with blocks made of poly (ethylene oxide) sterically 
stabilized (stealth) and may undergo less opsonization and uptake by the macrophages of RES, 
allowing the micelles to circulate longer in blood (Diego Chiappetta & Alejandro Sosnik, 2007). 
 
KINETICS OF DRUG RELEASE 
 The in-vitro release data was applied to various kinetic models to predict the mechanism 
of drug release of optimized formulation 
Table 14: Release Kinetics of Formulation F-6 
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Time 
(hrs) 
Log 
time 
(hrs) 
Square 
root of 
time (hrs) 
Cumulative 
% 
drug 
release 
Cumulative 
% 
drug 
remaining 
Log 
Cumulative 
% drug 
release 
Log 
Cumulative 
% drug 
remaining 
Cube root of 
Cumulative % 
drug 
remaining 
0 ∞ 0 0 100 ∞ 2 4.64 
0.5 -0.301 0.7071 1.59 98.41 0.2013 1.993 4.61 
1 0 1 3.18 96.82 0.5024 1.9859 4.59 
1.5 0.176 1.2247 5.6 94.4 0.7481 1.9749 4.55 
2 0.301 1.414 9.32 90.68 0.9694 1.9575 4.49 
3 0.4771 1.732 9.37 90.63 0.9717 1.9572 4.49 
4 0.602 2 9.7 90.3 0.9867 1.9556 4.48 
5 0.6989 2.236 10.02 89.98 1.0008 1.9541 4.48 
23 1.3617 4.7958 22.55 77.45 1.3531 1.889 4.26 
24 1.3802 4.8989 22.95 77.05 1.3607 1.8867 4.25 
25 1.3979 5 23.58 76.42 1.3725 1.8832 4.24 
26 1.4149 5.099 23.71 76.29 1.3749 1.8824 4.24 
27 1.4313 5.1961 24.38 75.62 1.387 1.8786 4.23 
28 1.4471 5.2915 24.78 75.22 1.3941 1.8763 4.22 
29 1.4623 5.3851 24.91 75.09 1.3963 1.8755 4.22 
47 1.672 6.8556 37.5 62.5 1.574 1.7958 3.97 
48 1.681 6.9282 37.97 62.03 1.5794 1.7926 3.96 
49 1.69 7 38.17 61.83 1.5817 1.7911 3.95 
50 1.698 7.071 38.64 61.36 1.587 1.7878 3.94 
51 1.7075 7.1414 39.12 60.88 1.5923 1.7844 3.93 
52 1.716 7.2111 39.32 60.68 1.5946 1.783 3.93 
53 1.7242 7.2801 39.8 60.2 1.5998 1.7795 3.92 
71 1.8512 8.4261 56.99 43.01 1.7557 1.6335 3.5 
72 1.8573 8.4852 57.29 42.71 1.758 1.6305 3.49 
73 1.8633 8.544 58.1 41.9 1.7642 1.6222 3.47 
74 1.8692 8.6023 58.41 41.59 1.7665 1.6189 3.46 
75 1.875 8.6602 59.25 40.75 1.7727 1.6101 3.44 
76 1.8808 8.7177 59.56 40.44 1.7749 1.6068 3.43 
77 1.8864 8.7749 60.41 39.59 1.7811 1.5975 3.41 
95 1.9777 9.7467 70.53 29.47 1.8483 1.4693 3.09 
96 1.9822 9.7979 70.9 29.1 1.8506 1.4638 3.08 
97 1.9867 9.8488 71.53 28.47 1.8545 1.4543 3.05 
98 1.9912 9.8994 72.41 27.59 1.8598 1.4407 3.02 
99 1.9956 9.9498 72.78 27.22 1.862 1.4348 3.01 
100 2 10 73.69 26.31 1.8674 1.4201 2.97 
101 2.0043 10.0498 74.06 25.94 1.8696 1.4139 2.96 
119 2.0755 10.9087 89.04 10.96 1.9495 1.0398 2.22 
120 2.0791 10.9544 89.5 10.5 1.9518 1.0211 2.19 
121 2.0827 11 90.46 9.54 1.9564 0.9795 2.12 
122 2.0863 11.0453 91.46 8.54 1.9612 0.9314 2.04 
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Fig. 12 : Zero-Order Release Kinetics of F-6 
 
 
 
 
Fig. 13: First Order Release Kinetics of F-6 
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Fig. 14 : Higuchi diffusion kinetics of F-6 
 
 
 
 
 
Fig. 15: Hixon Crowell Model Kinetics of F-6 
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Fig. 16: Korsemeyer- Peppas Model Kinetics of F-6 
 
 
 The optimized formulation (F-6) follows zero order kinetics in which the regression was 
0.9423. 
 The ‘n’value of Korsemeyer-Peppas equation was found to be 0.6476. From this it was 
concluded that the drug release follows non-fickian diffusion (Brahmankar & Sunil Jaiswal, 2009). 
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MAVERN PARTICLE SIZE ANALYSIS OF F-2 
 
Fig. 17: Statistics graph of F-2 formulation 
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Fig. 18: Size distribution by intensity of F-2 formulation 
 
 The maximum number of Raloxifene Hydrochloride loaded Micellar dispersions is distributed in the 
range of 11.70 to 68.06 nm. The average particle size of Raloxifene Hydrochloride loaded Micellar 
dispersions is 25.37 nm and PDI was found to be 0.513 
Results and Discussions 
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 MALVERN PARTICLE SIZE ANALYSIS OF F-2 
 
Fig. 19: Statistics graph of F-4 formulation 
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Fig. 20: Size distribution by intensity of F-4 formulation 
The maximum number of Raloxifene Hydrochloride loaded Micellar dispersions is distributed in the 
range of 43.82 to 220.2 nm. The average particle size of Raloxifene Hydrochloride loaded Micellar 
dispersions is 125.27 nm and PDI was found to be 0.679 
Results and Discussions 
 
Department of Pharmaceutics, Madras Medical College Page 60 
 
MALVERN PARTICLE SIZE ANALYSIS OF FORMULATION F-6 
 
Fig. 21: Statistics graph of F-6 formulation 
Results and Discussions 
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Fig. 22: Size distribution by intensity of F-6 formulation 
Results and Discussions 
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The maximum number of Raloxifene Hydrochloride loaded Micellar dispersions is distributed in the 
range of 3.615 to 21.04 nm. The average particle size of Raloxifene Hydrochloride loaded Micellar 
dispersions is 13.85 nm and PDI was found to be 0.465 
The average size of Raloxifene Hydrochloride loaded mixed micelles was found to be 25.37, 125.27 
and 13.85 nm for F-2, F-4, and F-6 respectively. The F-4 prepared with using 500mg of L121 and 250mg 
of F127 had larger size which may be due to lamellar aggregates formed by long propylene oxide 
chains(PO) and short EO chains in L121 (Kung T. Oh et al., 2004). A 1:1 ratio of L121/F127 mixtures with 
total PBC concentraton of 1g shows small particle size. In case of PDI, the values are found to be 0.573, 
0.679 and 0.465 for F-2, F-4 and F-6 respectively. So, it can be interpreted that F-6 micellar formulation 
will be more preferred for intestinal internalization due to it s comparatively smaller size and micelles 
shows best operated distribution algorithms (The Royal Society of Chemistry, 2015). 
 
SOLUBILITY: 
                Solubility of the drug in PBS pH 6.8 is 0.2335 mg/ml and for optimized formulation, it was 
found to be 1.3003 mg/ml.  
     The optimized formulation shows 5.5 fold increase in solubility when compared to drug 
alone. 
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MALVERN ZETA POTENTIAL ANALYSIS OF OPTIMIZED FORMULATION (F-6) 
 
Fig. 23: Zeta Potential report of optimized formulation 
Results and Discussions 
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The Zeta potential of the optimized formulation (F-6) was found to be -59.37 mV. This is 
due to highest HLB value of Pluronic F127, according to Anushree seth and Dhirendro S. Kothi 
(2012) the increased association of water (negatively charged hydroxyl groups) with the longer EO 
chain length of pluronic F127 resulted in increased negative zeta potential.  Thus, the results 
obtained confirms the distribution of PEO unit by pluronic F127 on the surface of the micelles, and 
as said by Diego Chiapetta and Alejandro Sosnik (2007) the micelles with blocks made of PEO are 
sterically stabilized and undergo less opsonization and uptake by macrophages of RES. The higher 
negative charge shows high colloidal stability.(Anushree Seth & Dhirendro Kothi, 2012)     
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SUPER RESOLUTION AND CONFOCAL MICROSCOPY 
 Super resolution and confocal microscopy images were seen for the optimized micelle 
dispersion. The results are shown in the following figure 23 & 24. 
 
 
 
Fig. 23: 2D (2 DIMENSION) SUPER RESOLUTION AND CONFOCAL MICROSCOPIC IMAGES 
OF RALOXIFENE HYDROCHLORIDE MICELLE DISPERSIONS 
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Fig. 24: 3D (3 DIMENSION) SUPER RESOLUTION AND CONFOCAL MICROSCOPIC IMAGES 
OF RALOXIFENE HYDROCHLORIDE MICELLE DISPERSIONS 
 The Super resolution and confocal microscopy analysis shows that the optimized 
polymeric  micellar formulation F-6 is discrete and spherical in shape. 
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             The Present investigation was undertaken with the objective to improve the poor 
aqueous solubility and the therapeutic efficacy of Raloxifene Hydrochloride by protection from 
extensive first pass metabolism and thereby improving the biovailability. 
 
             The aim of the present study is to formulate Raloxifene hydrochloride Polymeric Micelle 
drug delivery system using mixture of triblock copolymers, Pluronic L121 and F127 by thin film 
hydration method. 
 
All the formulations were prepared, evaluated and the following conclusions are made 
 The possibility of Drug-Excipient interaction was investigated by FT-IR study. The FT-
IR spectral analysis showed that there was no appearance or disappearance  of any characteristics 
peaks of pure drug in the physical mixture of drug and polymer and in the optimized 
formulation, which confirms the absence of chemical interaction between drug and polymer. 
 The entrapment efficiency of all the formulations was between 92 to 96%. It was found to 
be 94.75, 95, 94.16, 92.5, 95.5 and 95.83% for F-1, F-2, F-3, F-4, F-5 and F-6 respectively. 
            The in-vitro release shows that the increase in concentration of hydrophilic polymer 
(pluronic F127) results in faster release of drug and increase in the hydrophobic polymer 
(pluronic L121) concentration, sustains the release rate of drug 
           Though increase in pluronic L121 concentration shows sustained release, the use of F127 
is essential because it has longer PEO units. Thus using the same ratio of both L121 and F127 
may result in prolonged circulation as micelles with blocks made of poly (ethylene oxide) 
sterically stabilized (stealth) and may undergo less opsonization and uptake by the macrophages 
of RES, allowing the micelles to circulate longer in blood. 
            Investigation of order and mechanism of drug release by plotting the in-vitro data of 
optimized formulation F-6 for zero and first order, higuchi, hixon crowell and Korsemeyer 
peppas equation were made. The result shows that the formulation F-6 follows zero order 
kinetics in which the regression was 0.9423. The ‘n’ value of Korsemeyer – Peppas equation was 
found to be 0.6476. From this it is concluded that the drug release follows non fickian diffusion. 
            The Malvern particle size analysis of formulations F-2, F-4 and F-6 was made and the 
average size of micelles was found to be 25.37, 125.27 and 13.85 nm respectively. 
           The Polydispersity Index of F-2, F-4 and F-6 was 0.573, 0.679 and 0.465 respectively. 
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            From the result of particle size and polydispersity index it can be interpreted that F-6 
micellar formulation will be more preferred for intestinal internalization due to its comparatively 
smaller size and micelles shows best operated distribution algorithms. 
           Solubility of the candidate drug in phosphate buffered saline pH 6.8 is 233.5 µg/ml and 
for optimized formulation F-6, it is found to be 1300.3µg/ml. Thus, it can be concluded that the 
optimized formulation shows 5.5 fold increase in solubility when compared to drug alone. 
          The Zeta potential of the optimized formulation was found to be -59.37 mV. The results 
obtained confirms the distribution of PEO unit by pluronic F127 on the surface of the micelles. 
Hence, the  micelles are sterically stabilized and undergo less opsonization and uptake by 
macrophages of RES. The higher negative charge shows high colloidal stability. 
           The morphological studies using Super resolution and Confocal microscopy shows that 
the optimized formulation F-6 is discrete and spherical in shape. 
           Finally, the optimized formulation F-6 is concentrated by lyophilization using 
cryoprotectant (2.5%
w
/w Sucrose). 
 
FUTURE PLAN:  
 To study the pharmacokinetic parameters of the candidate drug which may 
include area under the plasma concentration-time curve (AUC), elimination half 
life (t
1
/2), volume of distribution (Vd), mean residence time (MRT) and clearance 
(Cl). 
 To perform the stability study 
 To assess the improved in-vitro therapeutic efficacy. 
 in-vivo studies and in vitro-vivo correlation studies. 
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